Details of Disease

General Information of Disease (ID: DIS59VMN)

• Disease Name: Psoriasis
• Disease Class: EA90: Psoriasis
• Definition: An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.
• Disease Hierarchy:
  DISAEGPH: Immune system disorder
  DISY5SZC: Dermatitis
  DISSCALK: Hereditary skin disorder
  DIS59VMN: Psoriasis
• ICD Code: ICD-11: ICD-11: EA90
• Disease Identifiers:
  MONDO ID: MONDO_0005083
  MESH ID: D011565
  UMLS CUI: C0033860
  MedGen ID: 10997
  SNOMED CT ID: 9014002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 16 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Atorvastatin	DMF28YC	Approved	Small molecular drug	[1]
Betamethasone	DMAHJEF	Approved	Small molecular drug	[2]
Calcipotriol	DM03CP7	Approved	Small molecular drug	[3]
Cortisone Acetate	DMG8K57	Approved	Small molecular drug	[4]
Dexamethasone	DMMWZET	Approved	Small molecular drug	[5]
Erlotinib	DMCMBHA	Approved	Small molecular drug	[6]
Hydrocortisone	DMGEMB7	Approved	Small molecular drug	[7]
Methotrexate	DM2TEOL	Approved	Small molecular drug	[8]
Methylprednisolone	DM4BDON	Approved	Small molecular drug	[9]
Nicotinamide	DMUPE07	Approved	Small molecular drug	[10]
Prednisolone	DMQ8FR2	Approved	Small molecular drug	[11]
Prednisone	DM2HG4X	Approved	Small molecular drug	[12]
Tazarotene	DM8SMD1	Approved	Small molecular drug	[13]
Triamcinolone	DM98IXF	Approved	Small molecular drug	[14]
Ustekinumab	DMHTYK3	Approved	Antibody	[15]
Vitamin B3	DMQVRZH	Approved	Small molecular drug	[16]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Benzylpenicillin	DMS9503	Phase 3	Small molecular drug	[17]
JNJ-77242113	DM6DLXK	Phase 2	NA	[19]
PF-07038124	DMI4RUI	Phase 2	Small molecule	[20]
JNJ-1459	DMEK1OJ	Phase 1	NA	[21]

This Disease is Treated as An Indication in 1 Drugs in Phase 2 Trial

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cyclosporin A	DMUYKBZ	Phase 2 Trial	Small molecular drug	[18]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DYV024	DM0TSOZ	Preclinical	NA	[22]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 250 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ALDH2	TTFLN4T	Limited	Genetic Variation	[23]
ANTXR2	TTOD34I	Limited	Genetic Variation	[24]
ATXN2	TTPQJ7P	Limited	Genetic Variation	[24]
CASR	TTBUYHA	Limited	Genetic Variation	[23]
CLCN6	TTCJRDO	Limited	Genetic Variation	[23]
CS	TTZA6B3	Limited	Genetic Variation	[25]
DNMT3A	TTJUALD	Limited	Genetic Variation	[24]
ERN1	TTKIAT3	Limited	Genetic Variation	[24]
ETS1	TTTGPSD	Limited	Genetic Variation	[24]
F9	TTFEZ5Q	Limited	Biomarker	[26]
GART	TTEXB9Z	Limited	Genetic Variation	[23]
GJB2	TTRGZX3	Limited	Genetic Variation	[27]
GPR183	TTME5YJ	Limited	Genetic Variation	[28]
GPR35	TT254XD	Limited	Genetic Variation	[24]
HDAC7	TTMUEK1	Limited	Genetic Variation	[24]
HLA-A	TTHONFT	Limited	Genetic Variation	[29]
HLA-DQA1	TTU2I3J	Limited	Genetic Variation	[30]
IFNGR2	TT13TL0	Limited	Genetic Variation	[24]
IL15	TTJFA35	Limited	Biomarker	[31]
IL19	TT87RWS	Limited	Altered Expression	[32]
IL20	TTNZMY2	Limited	Biomarker	[33]
IL21	TT9QEJ6	Limited	Altered Expression	[34]
KEAP1	TT3Z6Y9	Limited	Genetic Variation	[24]
KLRC1	TTC4IMS	Limited	Genetic Variation	[28]
KSR1	TTHL1TV	Limited	Genetic Variation	[24]
LRRK2	TTK0FEA	Limited	Genetic Variation	[24]
MGMT	TTJ8DV7	Limited	Genetic Variation	[25]
NOS2	TTF10I9	Limited	Genetic Variation	[24]
NPEPPS	TT371QC	Limited	Genetic Variation	[24]
NR5A2	TTAU3SY	Limited	Genetic Variation	[24]
OSMR	TTAH0KM	Limited	Genetic Variation	[24]
PDE4A	TTZ97H5	Limited	Biomarker	[35]
PPARG	TTT2SVW	Limited	Genetic Variation	[36]
PRKCB	TTYPXQF	Limited	Genetic Variation	[24]
PRKCQ	TT1MS7X	Limited	Genetic Variation	[24]
RGS6	TTJ96M8	Limited	Genetic Variation	[37]
RIC8B	TT26BHC	Limited	Genetic Variation	[24]
RPS6KB1	TTG0U4H	Limited	Genetic Variation	[24]
SH2B3	TT36N7Z	Limited	Genetic Variation	[24]
TLR7	TTRJ1K4	Limited	Posttranslational Modification	[38]
TNFRSF14	TTWGTC1	Limited	Genetic Variation	[24]
DAG1	TT4X7PG	moderate	Genetic Variation	[39]
DDX58	TTVB0O3	moderate	Biomarker	[40]
ITGB2	TTIJWR7	moderate	Genetic Variation	[41]
ACE2	TTUI5H7	Strong	Genetic Variation	[42]
ACKR1	TTKY2NS	Strong	Altered Expression	[43]
ADAM33	TTQICM2	Strong	Biomarker	[44]
ADRA1B	TTBRKXS	Strong	Genetic Variation	[45]
AHCY	TTE2KUJ	Strong	Biomarker	[46]
AHR	TT037IE	Strong	Genetic Variation	[47]
AKR1C3	TT5ZWB6	Strong	Biomarker	[48]
AKT3	TTO6SGY	Strong	Biomarker	[49]
ALOX12	TT12ABZ	Strong	Genetic Variation	[50]
AMOT	TTI48OS	Strong	Altered Expression	[51]
AOC1	TTM3B5R	Strong	Genetic Variation	[52]
AOC3	TT7HC21	Strong	Genetic Variation	[53]
APOB	TTN1IE2	Strong	Biomarker	[54]
APOE	TTKS9CB	Strong	Genetic Variation	[55]
AREG	TT76B3W	Strong	Biomarker	[56]
BMP6	TT07RIB	Strong	Altered Expression	[57]
BMX	TTN2I9E	Strong	Biomarker	[58]
BST2	TT90BJT	Strong	Biomarker	[59]
C5AR1	TTHXFA1	Strong	Biomarker	[60]
CA2	TTANPDJ	Strong	Genetic Variation	[61]
CALCA	TTVSFJW	Strong	Biomarker	[62]
CAPN1	TT1WBIJ	Strong	Biomarker	[63]
CARM1	TTIZQFJ	Strong	Biomarker	[64]
CASP5	TTWR48J	Strong	Altered Expression	[65]
CAT	TTPS279	Strong	Altered Expression	[66]
CCKAR	TTCG0AL	Strong	Genetic Variation	[67]
CCKBR	TTVFO0U	Strong	Genetic Variation	[67]
CCL17	TTMPHAE	Strong	Altered Expression	[68]
CCL20	TT2XAZY	Strong	Biomarker	[69]
CCR1	TTC24WT	Strong	Altered Expression	[70]
CCR4	TT7HQD0	Strong	Biomarker	[71]
CCR6	TTFDB30	Strong	Biomarker	[69]
CD1A	TTBGTFN	Strong	Biomarker	[72]
CD200	TT0BE68	Strong	Biomarker	[73]
CD27	TTDO1MV	Strong	Biomarker	[74]
CD40	TT1ERKL	Strong	Genetic Variation	[24]
CD6	TTMF6KC	Strong	Biomarker	[75]
CD69	TTPQE9F	Strong	Biomarker	[76]
CDK5R1	TTBYM6V	Strong	Biomarker	[77]
CFB	TTA0P7K	Strong	Genetic Variation	[78]
CMKLR1	TT4UGZL	Strong	Biomarker	[79]
COPS5	TTSTNJR	Strong	Altered Expression	[80]
CRHR1	TT7EFHR	Strong	Altered Expression	[81]
CRHR2	TTIY658	Strong	Biomarker	[82]
CSF2	TTNYZG2	Strong	Biomarker	[83]
CTSG	TTQAJF1	Strong	Biomarker	[84]
CTSS	TTUMQVO	Strong	Biomarker	[85]
CTSV	TTSD9T1	Strong	Altered Expression	[86]
CX3CL1	TT1OFBQ	Strong	Biomarker	[87]
CXCL10	TTQOVYA	Strong	Biomarker	[88]
CXCL11	TTWG0RE	Strong	Altered Expression	[89]
CXCL9	TTWE5PB	Strong	Altered Expression	[90]
CXCR1	TTMWT8Z	Strong	Altered Expression	[70]
CXCR2	TT30C9G	Strong	Altered Expression	[91]
CYP24A1	TT82UI1	Strong	Altered Expression	[92]
DEFB4A	TTIVY12	Strong	Genetic Variation	[93]
DUSP1	TTG8HIM	Strong	Biomarker	[94]
DUT	TTH6MBO	Strong	Biomarker	[95]
EGF	TTED8JB	Strong	Altered Expression	[96]
EIF2AK1	TTRUJBV	Strong	Genetic Variation	[97]
ERAP2	TTVGS1C	Strong	Genetic Variation	[98]
F13A1	TTXI2RA	Strong	Biomarker	[99]
FABP1	TTIV96N	Strong	Biomarker	[100]
FABP4	TTHWMFZ	Strong	Biomarker	[101]
FCGR2A	TTXT21W	Strong	Genetic Variation	[102]
FFAR2	TT0FYAN	Strong	Altered Expression	[103]
FGF19	TTGCH11	Strong	Altered Expression	[104]
FLT4	TTDCBX5	Strong	Altered Expression	[105]
FOSL1	TTY8LZG	Strong	Genetic Variation	[106]
FOSL2	TT689IR	Strong	Altered Expression	[107]
FPR2	TTOJ1NF	Strong	Biomarker	[108]
FURIN	TTH9WF6	Strong	Biomarker	[109]
GEM	TTAZF9M	Strong	Biomarker	[110]
GGH	TTZJRL0	Strong	Genetic Variation	[111]
GRHL2	TTUGH4C	Strong	Altered Expression	[112]
GRIN1	TTLD29N	Strong	Altered Expression	[113]
HAX1	TT21BYA	Strong	Altered Expression	[114]
HBEGF	TT15SL0	Strong	Altered Expression	[115]
HCAR2	TTWNV8U	Strong	Altered Expression	[103]
HNRNPA1	TTPJ9XK	Strong	Biomarker	[116]
HOXA5	TTXSVQP	Strong	Biomarker	[117]
HRH4	TTXJ178	Strong	Genetic Variation	[118]
HTR1A	TTSQIFT	Strong	Biomarker	[119]
HTR2A	TTJQOD7	Strong	Genetic Variation	[120]
IFNAR1	TTSYFMA	Strong	Altered Expression	[121]
IKZF3	TTCZVFZ	Strong	Genetic Variation	[122]
IL12RB2	TT4SWR8	Strong	Genetic Variation	[123]
IL13RA1	TTNEAMG	Strong	Altered Expression	[124]
IL13RA2	TTMPZ7V	Strong	Altered Expression	[125]
IL15RA	TTGN89I	Strong	Altered Expression	[126]
IL17D	TTC5LTG	Strong	Biomarker	[127]
IL1R1	TTWOTEA	Strong	Genetic Variation	[24]
IL1RAP	TTWS50K	Strong	Biomarker	[128]
IL1RL2	TTUS18T	Strong	Biomarker	[129]
IL21R	TTZO9B0	Strong	Altered Expression	[130]
IL24	TT1EPXZ	Strong	Genetic Variation	[131]
IL25	TTVMO5W	Strong	Biomarker	[132]
IL2RA	TT10Y9E	Strong	Genetic Variation	[24]
IL31	TT1RJXK	Strong	Biomarker	[133]
IL32	TTD4G7L	Strong	Altered Expression	[134]
IL36G	TT8SLDN	Strong	Altered Expression	[135]
IL4	TTLGTKB	Strong	Biomarker	[136]
IL4R	TTDWHC3	Strong	Altered Expression	[124]
IL7	TT8FRMO	Strong	Biomarker	[137]
IL9	TT0JTFD	Strong	Biomarker	[138]
ITGAE	TTH0Z37	Strong	Biomarker	[76]
ITGAL	TT48WR6	Strong	Genetic Variation	[24]
JAK1	TT6DM01	Strong	Biomarker	[139]
KLK5	TTULSEW	Strong	Biomarker	[140]
KLK6	TTLPF4X	Strong	Biomarker	[141]
KLK7	TTE6GTB	Strong	Altered Expression	[142]
KLK8	TTH5MRS	Strong	Biomarker	[141]
LAMP1	TTC214J	Strong	Biomarker	[143]
LANCL1	TTZW8NS	Strong	Biomarker	[138]
LTA	TTP73TM	Strong	Genetic Variation	[144]
LYN	TT1RWNJ	Strong	Altered Expression	[145]
LYVE1	TTG8DNU	Strong	Biomarker	[146]
MALT1	TTCI81G	Strong	Biomarker	[147]
MAPKAPK2	TTMUG9D	Strong	Altered Expression	[148]
MBTPS1	TTNSM2I	Strong	Biomarker	[149]
MC1R	TT0MV2T	Strong	Genetic Variation	[150]
MCHR1	TTX4RTB	Strong	Biomarker	[151]
MKI67	TTB4UNG	Strong	Biomarker	[152]
MMP10	TTXLEG7	Strong	Biomarker	[153]
NAGLU	TTDM6HZ	Strong	Genetic Variation	[154]
NEDD8	TTNDC4K	Strong	Altered Expression	[155]
NFKBIA	TTSHAEB	Strong	Genetic Variation	[156]
NOTCH4	TTXDIK2	Strong	Biomarker	[157]
NPSR1	TTV1C0Z	Strong	Genetic Variation	[158]
NR1H3	TTECBXN	Strong	Biomarker	[159]
NTSR1	TTTUMEP	Strong	Biomarker	[160]
OLR1	TTKSND3	Strong	Altered Expression	[161]
OPRK1	TTQW87Y	Strong	Altered Expression	[162]
OPRM1	TTKWM86	Strong	Genetic Variation	[163]
PCNA	TTLG1PD	Strong	Biomarker	[164]
PDE3A	TT06AWU	Strong	Biomarker	[165]
PDE4B	TTVIAT9	Strong	Altered Expression	[166]
PDE7A	TT1BC3A	Strong	Biomarker	[167]
PECAM1	TT4EZB2	Strong	Biomarker	[168]
PLA2G7	TTDNFMT	Strong	Biomarker	[169]
POLR2G	TTD4YFP	Strong	Altered Expression	[170]
PRKCZ	TTBSN0L	Strong	Altered Expression	[171]
PSMB8	TTEAD9J	Strong	Biomarker	[172]
PSMB9	TTOUSTQ	Strong	Biomarker	[172]
PTPN2	TTY8PUS	Strong	Genetic Variation	[173]
QPCT	TTJ7YTV	Strong	Biomarker	[174]
REG3A	TTL4H8N	Strong	Altered Expression	[175]
REN	TTB2MXP	Strong	Biomarker	[176]
RIPK1	TTVJHX8	Strong	Biomarker	[177]
RNF7	TTODWGT	Strong	Genetic Variation	[178]
RPS6KA5	TTYXEPL	Strong	Biomarker	[179]
RPSA	TTLUW5B	Strong	Biomarker	[138]
RUNX3	TTKCVO7	Strong	Biomarker	[180]
RYR1	TTU5CIX	Strong	Genetic Variation	[181]
S100A9	TT0TMQG	Strong	Biomarker	[182]
S100B	TTQ0V86	Strong	Altered Expression	[183]
S1PR1	TT9JZCK	Strong	Biomarker	[184]
SAA1	TTY0DN9	Strong	Altered Expression	[185]
SCARB1	TTRE324	Strong	Biomarker	[186]
SELP	TTE5VG0	Strong	Biomarker	[187]
SELPLG	TTS5K8U	Strong	Altered Expression	[188]
SEMA3A	TTVKD3S	Strong	Biomarker	[189]
SEMA4D	TT5UT28	Strong	Biomarker	[190]
SLC22A1	TTM5Q4V	Strong	Genetic Variation	[191]
SLCO1B1	TTFGXEB	Strong	Genetic Variation	[191]
SLCO1C1	TT340CE	Strong	Biomarker	[165]
SMAD3	TTHQZV7	Strong	Genetic Variation	[24]
SPHK2	TTCN0M9	Strong	Biomarker	[192]
STAB1	TTJFEOC	Strong	Biomarker	[193]
SULF2	TTLQTHB	Strong	Biomarker	[194]
TBK1	TTMP03S	Strong	Biomarker	[195]
TEK	TT9VGXW	Strong	Altered Expression	[196]
TFPI	TT068JH	Strong	Biomarker	[197]
TGFA	TTTLQFR	Strong	Biomarker	[198]
TGM1	TT7A949	Strong	Altered Expression	[199]
TLR2	TTY7ZHS	Strong	Genetic Variation	[200]
TLR4	TTISGCA	Strong	Altered Expression	[201]
TLR6	TTWRI8V	Strong	Altered Expression	[202]
TLR8	TT8CWFK	Strong	Altered Expression	[203]
TLR9	TTSHG0T	Strong	Genetic Variation	[204]
TNFRSF13B	TTL9OD4	Strong	Altered Expression	[205]
TNFRSF13C	TT7NJSE	Strong	Biomarker	[206]
TNFRSF17	TTZ3P4W	Strong	Biomarker	[206]
TNFRSF1A	TTG043C	Strong	Genetic Variation	[24]
TNFRSF4	TTL31H0	Strong	Altered Expression	[107]
TNFSF12	TTBTDM1	Strong	Biomarker	[207]
TNFSF15	TTEST6I	Strong	Genetic Variation	[208]
TRIM27	TTTO3QN	Strong	Altered Expression	[209]
TRPV1	TTMI6F5	Strong	Biomarker	[210]
TSLP	TTHMW3T	Strong	Altered Expression	[211]
TXK	TT8M1DP	Strong	Biomarker	[212]
TYK2	TTBYWP2	Strong	Biomarker	[213]
USP2	TTUEQ1W	Strong	Biomarker	[214]
ACR	TTAHE2N	Definitive	Biomarker	[215]
ADAM17	TT6AZXG	Definitive	Biomarker	[216]
CCL22	TTBTWI1	Definitive	Biomarker	[217]
CXCL1	TTLK1RW	Definitive	Biomarker	[218]
FCGR3A	TTIFOC0	Definitive	Genetic Variation	[219]
FGF7	TTFY134	Definitive	Biomarker	[220]
JUN	TTS7IR5	Definitive	Altered Expression	[221]
KYNU	TTWQM3J	Definitive	Biomarker	[222]
PPARD	TT2JWF6	Definitive	Biomarker	[223]
SELE	TT1PL7M	Definitive	Biomarker	[224]
SERPINB3	TT6QLPX	Definitive	Altered Expression	[225]
TNFRSF1B	TT63WSF	Definitive	Genetic Variation	[226]
WNT5A	TTKG7F8	Definitive	Altered Expression	[227]

This Disease Is Related to 10 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
KCNH7	DT3WXPI	Limited	Genetic Variation	[25]
SLC39A11	DTEOAND	Limited	Genetic Variation	[24]
SLC9A8	DTNY0C2	Limited	Genetic Variation	[24]
SLC12A8	DT0OA2B	Strong	Genetic Variation	[228]
SLC25A20	DTQOUM4	Strong	Genetic Variation	[61]
SLC25A5	DTL1TRY	Strong	Altered Expression	[229]
SLC52A1	DT7NOKR	Strong	Biomarker	[230]
SLC7A9	DTP7AEQ	Strong	Biomarker	[157]
SLC9C2	DT2N5HO	Strong	Biomarker	[231]
SLCO6A1	DTIFXNS	Strong	Genetic Variation	[232]

This Disease Is Related to 13 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
PARK7	DEPOVCH	Limited	Genetic Variation	[24]
ACOT13	DEMK5U6	Strong	Biomarker	[233]
AKR1B10	DEP6GT1	Strong	Biomarker	[234]
AKR1C1	DE7P2FB	Strong	Biomarker	[48]
CYP27A1	DEBS639	Strong	Altered Expression	[235]
CYP27B1	DE3FYEM	Strong	Biomarker	[235]
CYP2S1	DE6NMGO	Strong	Biomarker	[236]
IPMK	DESA9EX	Strong	Genetic Variation	[237]
MSMO1	DE5FUD0	Strong	Biomarker	[238]
NAT1	DE7OAB3	Strong	Genetic Variation	[239]
SCLY	DEH4TD6	Strong	Genetic Variation	[240]
TGM3	DEOEB3Q	Strong	Biomarker	[241]
TGM5	DEW8QEH	Strong	Biomarker	[242]

This Disease Is Related to 407 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACO1	OT2VUR7L	Limited	Genetic Variation	[25]
ACTA2	OTEDLG8E	Limited	Genetic Variation	[24]
ADCY3	OTGOQM6B	Limited	Genetic Variation	[24]
AP5B1	OTZGM9QA	Limited	Genetic Variation	[23]
ASAP2	OTGEXULW	Limited	Genetic Variation	[24]
ATG16L1	OTEOYC5D	Limited	Genetic Variation	[24]
ATG5	OT4T5SMS	Limited	Genetic Variation	[24]
BACH2	OT17GS18	Limited	Genetic Variation	[24]
BLOC1S2	OTUR3E76	Limited	Genetic Variation	[28]
BPTF	OTD1RZAD	Limited	Genetic Variation	[23]
BSN	OTZ72VIB	Limited	Genetic Variation	[24]
C17orf67	OTCL5EE8	Limited	Genetic Variation	[24]
C1orf141	OTASPHL0	Limited	Genetic Variation	[24]
CAMK2G	OTHD9KJG	Limited	Genetic Variation	[243]
CARD9	OTJ81AWD	Limited	Genetic Variation	[24]
CAST	OTBXZZGF	Limited	Genetic Variation	[25]
CAVIN1	OTFO915U	Limited	Genetic Variation	[244]
CCHCR1	OT22C116	Limited	Genetic Variation	[245]
CDKN2D	OT2TTZPZ	Limited	Biomarker	[26]
CFL1	OTT6D5MH	Limited	Genetic Variation	[28]
CHST8	OTQT4TKR	Limited	Genetic Variation	[25]
CLEC16A	OTLGV5SV	Limited	Genetic Variation	[24]
CMC1	OTCWYKPI	Limited	Genetic Variation	[24]
CPEB4	OTW1SCZW	Limited	Genetic Variation	[24]
CREM	OTJIJ5AL	Limited	Genetic Variation	[24]
DAP	OT5YLL7E	Limited	Genetic Variation	[24]
DENND1B	OT3VCNPE	Limited	Genetic Variation	[24]
DNAJB4	OTUD01BK	Limited	Genetic Variation	[28]
DONSON	OTN5HE0W	Limited	Genetic Variation	[23]
ELMO1	OTY2ORXK	Limited	Genetic Variation	[25]
ELOA	OTOQTF5K	Limited	Genetic Variation	[25]
EXOC2	OT5QG1WG	Limited	Genetic Variation	[25]
FAM118A	OT6EM97E	Limited	Genetic Variation	[24]
FAM177A1	OTXTA14N	Limited	Genetic Variation	[24]
FIBP	OTI7131S	Limited	Genetic Variation	[24]
GAL3ST2	OTZT1PLE	Limited	Genetic Variation	[24]
GCKR	OTSIWXGG	Limited	Genetic Variation	[24]
GIPC2	OT68YFO1	Limited	Genetic Variation	[28]
GLYAT	OT3WWYXD	Limited	Genetic Variation	[24]
GNA12	OT3IRZH3	Limited	Genetic Variation	[24]
GPR160	OTMXJT73	Limited	Genetic Variation	[23]
HIPK1	OTSEA8RS	Limited	Genetic Variation	[24]
ICAM5	OTDGGAFH	Limited	Genetic Variation	[25]
IFIH1	OTZA2AHA	Limited	Biomarker	[246]
IKBKE	OT5VYOSM	Limited	Genetic Variation	[28]
IL17B	OTS86H50	Limited	Biomarker	[33]
IL17RA	OTVVI8ER	Limited	Genetic Variation	[247]
IL18R1	OT83XMPQ	Limited	Genetic Variation	[24]
IL6R	OTCQL07Z	Limited	Genetic Variation	[24]
INAVA	OTGXNB86	Limited	Genetic Variation	[24]
IRGM	OTKD3O5Z	Limited	Genetic Variation	[24]
ITPRID1	OT9MH0BX	Limited	Genetic Variation	[23]
KLF13	OTMIKHZ4	Limited	Genetic Variation	[28]
KPRP	OTRJF3OY	Limited	Genetic Variation	[23]
LRRC43	OTCINBGT	Limited	Genetic Variation	[28]
MFSD4B	OTHHKWRT	Limited	Genetic Variation	[244]
MST1	OTOC4UNG	Limited	Genetic Variation	[24]
MYPN	OTHTOFDU	Limited	Genetic Variation	[23]
MYRF	OTKF6AEB	Limited	Genetic Variation	[24]
MYT1L	OTV45MAS	Limited	Genetic Variation	[25]
NDFIP1	OTIORSWF	Limited	Genetic Variation	[24]
NPPA	OTMQNTNX	Limited	Genetic Variation	[23]
PAK5	OT32WQGL	Limited	Genetic Variation	[244]
PKIG	OTOIWE5G	Limited	Genetic Variation	[24]
PLCL2	OTK5FDF6	Limited	Genetic Variation	[243]
POLI	OTBA4DCE	Limited	Genetic Variation	[244]
PPP2R3C	OT7E6V9B	Limited	Genetic Variation	[24]
PRDM1	OTQLSVBS	Limited	Genetic Variation	[24]
PRORP	OTWIS44P	Limited	Genetic Variation	[25]
PTPRN2	OTL6SH28	Limited	Genetic Variation	[25]
PUS10	OTFFJWZX	Limited	Genetic Variation	[24]
QTRT1	OTC33MCV	Limited	Genetic Variation	[25]
RAD50	OTYMU9G1	Limited	Genetic Variation	[25]
RASIP1	OTCRY2AN	Limited	Genetic Variation	[25]
RAVER1	OTMHBTLE	Limited	Genetic Variation	[24]
RBM45	OTWTHD77	Limited	Biomarker	[248]
RDX	OTNSYUN6	Limited	Genetic Variation	[24]
REG1A	OTMHUH1D	Limited	Biomarker	[26]
REV3L	OT0OP8EJ	Limited	Genetic Variation	[244]
RMI2	OTA0HP4S	Limited	Genetic Variation	[24]
RNF114	OTF06FRP	Limited	Biomarker	[249]
RNF145	OTBCTG4A	Limited	Genetic Variation	[23]
RPS26	OTBYTA6A	Limited	Genetic Variation	[25]
SBNO2	OT1C6J3K	Limited	Genetic Variation	[24]
SCRN1	OTELM5C2	Limited	Genetic Variation	[23]
SETD1A	OTVVWRIC	Limited	Genetic Variation	[24]
SKAP2	OTSF44KP	Limited	Genetic Variation	[24]
SLIT3	OTU8MKEU	Limited	Genetic Variation	[25]
SON	OT9VWV18	Limited	Genetic Variation	[23]
SP140	OTQZHFMT	Limited	Genetic Variation	[24]
STK11	OT1YZSP3	Limited	Genetic Variation	[24]
STX1B	OTSW59X0	Limited	Genetic Variation	[244]
SYNE2	OTBUXGQ0	Limited	Genetic Variation	[23]
THADA	OTYZQX0F	Limited	Genetic Variation	[24]
TMEM258	OTXSDU14	Limited	Genetic Variation	[24]
TRIM65	OTSQTK3A	Limited	Genetic Variation	[28]
TSPAN14	OT29167O	Limited	Genetic Variation	[24]
ADCY7	OTAWMGP3	moderate	Genetic Variation	[39]
ADGRL2	OTCXD2YR	moderate	Genetic Variation	[39]
ANKRD30A	OTJXYAE5	moderate	Genetic Variation	[39]
ATXN2L	OTP5M3R9	moderate	Genetic Variation	[39]
CRB1	OTXYUNG0	moderate	Genetic Variation	[39]
FNBP1	OTSJ5KKA	moderate	Genetic Variation	[39]
INS-IGF2	OTZR74BO	moderate	Genetic Variation	[39]
LURAP1L	OTSJ29M5	moderate	Genetic Variation	[39]
NKD1	OTY3MO97	moderate	Genetic Variation	[39]
SUOX	OTEJQ9FC	moderate	Genetic Variation	[39]
AATK	OTVHAX5N	Strong	Genetic Variation	[250]
ACD	OTC54EPO	Strong	Biomarker	[251]
ACKR2	OTWYY14H	Strong	Biomarker	[252]
ACOT8	OTHY684G	Strong	Altered Expression	[253]
AIM2	OT86QUI8	Strong	Biomarker	[254]
ALOX15B	OTWQQ08W	Strong	Genetic Variation	[50]
ANGPTL6	OTOQ5W67	Strong	Biomarker	[255]
ANKRD55	OT62KZII	Strong	Genetic Variation	[24]
ANXA6	OT9KIQ0Y	Strong	Genetic Variation	[25]
ARHGEF2	OTBQTFRT	Strong	Biomarker	[138]
ARMH1	OTTJC0D6	Strong	Biomarker	[138]
ATP5F1A	OT3FZDLX	Strong	Biomarker	[256]
AZI2	OT61Q7Q8	Strong	Altered Expression	[253]
B3GNT2	OTE69HV8	Strong	Altered Expression	[257]
B3GNTL1	OTYWGHF1	Strong	Altered Expression	[257]
BAIAP3	OTS1H0J0	Strong	Altered Expression	[258]
BANK1	OTXAAA11	Strong	Genetic Variation	[24]
BCAP31	OTKSACR4	Strong	Altered Expression	[259]
BCL10	OT47MCLI	Strong	Altered Expression	[147]
BCL3	OT1M5B95	Strong	Biomarker	[260]
BTD	OTJYTQ69	Strong	Altered Expression	[258]
BTNL2	OTTTEMZA	Strong	Genetic Variation	[261]
BTRC	OT2EZDGR	Strong	Biomarker	[262]
C16orf82	OT77Z5Y5	Strong	Biomarker	[54]
CADM2	OT45PVKC	Strong	Genetic Variation	[263]
CALML5	OTOFJLFA	Strong	Biomarker	[241]
CBLIF	OTNE20WU	Strong	Altered Expression	[264]
CCL19	OTQ2UJMH	Strong	Biomarker	[265]
CCL4	OT6B8P25	Strong	Biomarker	[102]
CCL4L2	OTDBSXOU	Strong	Biomarker	[102]
CCL7	OTDIS99H	Strong	Biomarker	[266]
CCR10	OT7ZWSSD	Strong	Biomarker	[267]
CCRL2	OT5PX0RX	Strong	Genetic Variation	[97]
CD1B	OT4D5EG7	Strong	Biomarker	[268]
CD1C	OT4XINUJ	Strong	Biomarker	[268]
CD1D	OT3ROU4J	Strong	Biomarker	[269]
CD226	OT4UG0KB	Strong	Genetic Variation	[24]
CD244	OTSMR85N	Strong	Biomarker	[270]
CD84	OTAY5B0F	Strong	Genetic Variation	[271]
CD93	OT6HZT6H	Strong	Genetic Variation	[272]
CDC6	OTX93FE7	Strong	Altered Expression	[273]
CDCA5	OTZLCQ5U	Strong	Biomarker	[77]
CDKAL1	OTA0SGNE	Strong	Genetic Variation	[24]
CEBPD	OTNBIPMY	Strong	Biomarker	[274]
CETN1	OTGQ8JOZ	Strong	Altered Expression	[275]
CHI3L1	OT2Z7VJH	Strong	Biomarker	[153]
CKLF	OTHLPHA0	Strong	Biomarker	[276]
CLC	OTYMYR85	Strong	Genetic Variation	[277]
CLDN3	OT71MN9S	Strong	Biomarker	[278]
CLEC7A	OTRTBH27	Strong	Biomarker	[279]
CLMN	OT7U5J3T	Strong	Biomarker	[102]
CNTN3	OTC1274J	Strong	Biomarker	[280]
COG6	OTDLQITC	Strong	Genetic Variation	[281]
COPE	OTBKHBT7	Strong	Biomarker	[282]
CP	OTM8JE4Y	Strong	Biomarker	[283]
CPQ	OTTNZNLD	Strong	Biomarker	[284]
CRABP1	OTISDG5X	Strong	Biomarker	[285]
CRNN	OTAORBR4	Strong	Altered Expression	[286]
CSMD1	OTIVDSC4	Strong	Genetic Variation	[25]
CST6	OTZVHJTF	Strong	Altered Expression	[86]
DDX39A	OT0Z6E1K	Strong	Biomarker	[157]
DDX39B	OTEVCFVU	Strong	Biomarker	[157]
DEFB104A	OTLQZR6K	Strong	Altered Expression	[287]
DGCR8	OT62LXE4	Strong	Altered Expression	[288]
DLAT	OT9LBJVN	Strong	Biomarker	[289]
DMKN	OTRIGZMK	Strong	Biomarker	[290]
DMXL2	OTB4JWN3	Strong	Biomarker	[291]
DUOX1	OTQ2AEW0	Strong	Biomarker	[292]
EBNA1BP2	OTBRVMZH	Strong	Biomarker	[138]
ECM1	OT1K65VW	Strong	Biomarker	[51]
EDA	OTAKS5WS	Strong	Altered Expression	[293]
EDIL3	OTDVVNS0	Strong	Biomarker	[51]
EHF	OTY6TPWD	Strong	Biomarker	[106]
EMP1	OTSZHUHQ	Strong	Altered Expression	[294]
ETFA	OTXX61VZ	Strong	Biomarker	[295]
FABP7	OTRE2H4G	Strong	Altered Expression	[182]
FAM20B	OTOA0UYT	Strong	Biomarker	[296]
FANCE	OTKRPBW1	Strong	Biomarker	[297]
FBXL19	OTGDHPOE	Strong	Genetic Variation	[25]
FCGR3B	OTSLSPZG	Strong	Biomarker	[298]
FCN2	OTTHJBKZ	Strong	Biomarker	[77]
FGD5	OT5VIRP2	Strong	Altered Expression	[193]
FNDC3A	OTUX3S2I	Strong	Genetic Variation	[24]
FUT2	OTLXM6WI	Strong	Biomarker	[299]
FYCO1	OTKZHTZ5	Strong	Biomarker	[300]
FZD2	OT952ML1	Strong	Genetic Variation	[301]
FZD5	OTXFFY56	Strong	Biomarker	[302]
FZD8	OTZ9IRFL	Strong	Biomarker	[302]
GALR3	OTXU6PKO	Strong	Biomarker	[303]
GCHFR	OTEOT8GI	Strong	Biomarker	[77]
GLIS1	OTBDNB26	Strong	Altered Expression	[304]
GNLY	OTZJKA8C	Strong	Biomarker	[305]
GOT2	OT6XBWN0	Strong	Biomarker	[100]
GPR15	OTK8674M	Strong	Biomarker	[306]
GPRC5A	OTPOCWR7	Strong	Altered Expression	[307]
GRHL3	OT1V4ZEH	Strong	Altered Expression	[308]
GSTK1	OTDNGWAF	Strong	Genetic Variation	[232]
GSTM2	OTG4WT05	Strong	Genetic Variation	[309]
GZMA	OT43R33L	Strong	Biomarker	[310]
HAT1	OT307KEN	Strong	Biomarker	[311]
HCP5	OTV0YRI8	Strong	Genetic Variation	[312]
HLA-DMB	OT17HGXJ	Strong	Biomarker	[313]
HLA-DOA	OTZE5Q7R	Strong	Genetic Variation	[314]
HLA-DQA2	OT1DH0N9	Strong	Genetic Variation	[315]
HLA-DRB5	OTUX5TWM	Strong	Genetic Variation	[237]
HLA-E	OTX1CTFB	Strong	Biomarker	[316]
HSPA14	OTZCA5LK	Strong	Altered Expression	[317]
IARS1	OT9WXH5N	Strong	Biomarker	[318]
ID4	OTPMJ39I	Strong	Posttranslational Modification	[319]
IFI16	OT4SPU0U	Strong	Biomarker	[320]
IFI27	OTI2XGIT	Strong	Biomarker	[321]
IFI6	OTWOOAM4	Strong	Altered Expression	[322]
IFNLR1	OTWWWK45	Strong	Biomarker	[323]
IL12RB1	OTM1IJO2	Strong	Biomarker	[324]
IL17C	OTKXIVNQ	Strong	Biomarker	[325]
IL17RC	OTEFOBSS	Strong	Altered Expression	[326]
IL17RD	OTKD9XST	Strong	Altered Expression	[327]
IL1F10	OTJAASGC	Strong	Biomarker	[328]
IL20RA	OTSIVBVS	Strong	Genetic Variation	[329]
IL20RB	OTHFXK95	Strong	Genetic Variation	[329]
IL22RA1	OTGVKLBR	Strong	Altered Expression	[330]
IL22RA2	OTGOFDCY	Strong	Biomarker	[331]
IL26	OT2WYCW4	Strong	Biomarker	[332]
IL27	OTIS3OF8	Strong	Biomarker	[127]
IL36B	OTYT4LP5	Strong	Biomarker	[93]
IL36RN	OT5CO95A	Strong	Genetic Variation	[333]
IL9R	OTILCLXA	Strong	Altered Expression	[334]
IRF2	OTAZRUW3	Strong	Genetic Variation	[335]
ISG20	OTCWRJJW	Strong	Biomarker	[336]
ISYNA1	OT49ONSE	Strong	Genetic Variation	[337]
ITGAX	OTOGIMHE	Strong	Biomarker	[338]
ITLN1	OT7ZLJVV	Strong	Genetic Variation	[339]
IVL	OT4VPNGY	Strong	Altered Expression	[340]
JAM2	OTHVJJRJ	Strong	Biomarker	[341]
JAZF1	OTXTYSYD	Strong	Genetic Variation	[342]
JUNB	OTG2JXV5	Strong	Altered Expression	[221]
KHDRBS3	OTUG02U7	Strong	Altered Expression	[294]
KIR2DL5A	OT09FZE1	Strong	Altered Expression	[343]
KIR3DL1	OTPOSXFX	Strong	Biomarker	[110]
KIR3DS1	OTJWIO4T	Strong	Genetic Variation	[344]
KLK11	OT5PKX7Y	Strong	Altered Expression	[142]
KLLN	OTV3FPH0	Strong	Biomarker	[345]
KLRC2	OTT4N86S	Strong	Genetic Variation	[316]
KRT10	OTSVRD3Q	Strong	Biomarker	[346]
KRT14	OTUVZ1DW	Strong	Genetic Variation	[347]
LCE3A	OTOJUELU	Strong	Altered Expression	[348]
LCE3D	OTNAIJSE	Strong	Biomarker	[349]
LHFPL6	OTY6LHJY	Strong	Genetic Variation	[123]
LMO4	OT5NDCT9	Strong	Biomarker	[350]
LRRFIP1	OTN7XAUD	Strong	Biomarker	[351]
LYNX1	OTK4103B	Strong	Biomarker	[352]
MAVS	OTTQ0J64	Strong	Biomarker	[246]
MED15	OT0D0JVD	Strong	Altered Expression	[307]
MGAT5	OTU4DD4G	Strong	Biomarker	[353]
MIB1	OT5C404P	Strong	Biomarker	[152]
MMP19	OTLSTT2B	Strong	Altered Expression	[354]
MNAT1	OTXLOYCB	Strong	Biomarker	[77]
MOCOS	OT0TL3Q5	Strong	Genetic Variation	[355]
MXRA7	OTVQLYIY	Strong	Biomarker	[356]
MYOM2	OTD2UOXW	Strong	Biomarker	[357]
NAA25	OTS3QVF1	Strong	Altered Expression	[253]
NANS	OTMQ2FUH	Strong	Biomarker	[358]
NAP1L1	OTI7WBZV	Strong	Altered Expression	[253]
NAPSA	OT6F8IAL	Strong	Altered Expression	[253]
NAT9	OT4ZKCRS	Strong	Genetic Variation	[359]
NBAS	OTW9IBRI	Strong	Genetic Variation	[154]
NCKAP1	OTEZQXXJ	Strong	Altered Expression	[253]
NCOA5	OTOGWTWB	Strong	Genetic Variation	[360]
NFATC1	OT4TMERS	Strong	Genetic Variation	[24]
NFATC4	OTTDCUAO	Strong	Altered Expression	[361]
NFKBIL1	OTYFTPS0	Strong	Biomarker	[362]
NLN	OTFRITPU	Strong	Altered Expression	[363]
NME2	OTCYGLHV	Strong	Altered Expression	[364]
NRIP1	OTIZOJQV	Strong	Biomarker	[365]
NRTN	OT4PAKUY	Strong	Biomarker	[366]
OAS2	OT64CCTM	Strong	Altered Expression	[367]
OLIG3	OTU8XLAF	Strong	Biomarker	[368]
OPN4	OT1LZ7TS	Strong	Altered Expression	[363]
OPTC	OTCASGO0	Strong	Biomarker	[369]
OR2AG1	OTEITRP4	Strong	Genetic Variation	[370]
ORM1	OTZKSBRE	Strong	Biomarker	[256]
OSCP1	OTZ4IFGJ	Strong	Biomarker	[371]
OXA1L	OTS0BFRD	Strong	Biomarker	[372]
PCDHGA12	OT3JJI7L	Strong	Altered Expression	[373]
PCLAF	OTMVIOUU	Strong	Biomarker	[374]
PDC	OT1UUVYY	Strong	Biomarker	[211]
PDPN	OTBUV19I	Strong	Biomarker	[375]
PDZK1IP1	OTWA6M5K	Strong	Altered Expression	[376]
PGLYRP1	OTBTPR2T	Strong	Genetic Variation	[377]
PGLYRP3	OT5C7PRT	Strong	Genetic Variation	[378]
PGLYRP4	OTI115BR	Strong	Genetic Variation	[378]
PI3	OT47MTC3	Strong	Altered Expression	[379]
PIAS4	OTB7SVMZ	Strong	Genetic Variation	[380]
PIK3IP1	OTWE5G4T	Strong	Biomarker	[351]
PIPOX	OTWTCOTN	Strong	Biomarker	[381]
PLA2G10	OTRZ2L5A	Strong	Biomarker	[382]
PLCD1	OT6WFVXZ	Strong	Biomarker	[383]
PLXNB2	OT56I2VD	Strong	Biomarker	[190]
PNISR	OTUM02FW	Strong	Biomarker	[384]
POMP	OTMPM1P5	Strong	Biomarker	[385]
PPBP	OT1FHGQS	Strong	Altered Expression	[386]
PPP3R1	OTGQNFJQ	Strong	Biomarker	[387]
PPP6C	OTR1STMJ	Strong	Biomarker	[388]
PRELP	OT9EEBUJ	Strong	Altered Expression	[294]
PRKRA	OTUTVZZU	Strong	Genetic Variation	[25]
PROK2	OT70IFEZ	Strong	Biomarker	[389]
PRR9	OT4ZHG7T	Strong	Genetic Variation	[390]
PSAP	OTUOEKY7	Strong	Altered Expression	[391]
PSMD7	OT7PZZ4K	Strong	Biomarker	[138]
PSORS1C1	OT9HK436	Strong	Genetic Variation	[392]
PSORS1C2	OTK43GE4	Strong	Genetic Variation	[393]
PTTG1	OTIMYS4W	Strong	Genetic Variation	[45]
PTTG2	OTXGZ8FV	Strong	Biomarker	[394]
PWP1	OTUKXP1E	Strong	Biomarker	[395]
R3HCC1L	OT776PX2	Strong	Biomarker	[396]
RAB40B	OTCA9ZF5	Strong	Genetic Variation	[397]
RABEPK	OTCZSREH	Strong	Biomarker	[138]
RARRES1	OTETUPP5	Strong	Altered Expression	[307]
RARRES2	OT1BJE8K	Strong	Biomarker	[398]
RBP1	OTRP1MFC	Strong	Biomarker	[399]
RETN	OTW5Z1NH	Strong	Altered Expression	[400]
RNASE7	OTIXO0Z4	Strong	Biomarker	[401]
ROBO3	OTPVG40S	Strong	Biomarker	[40]
RPA1	OT76POLP	Strong	Biomarker	[402]
RTL1	OTOT33IM	Strong	Biomarker	[403]
S100A14	OTVFJJ91	Strong	Altered Expression	[275]
SAA2	OTYAVJWG	Strong	Altered Expression	[185]
SCN7A	OTK05PXY	Strong	Genetic Variation	[154]
SCUBE1	OT4JY1UY	Strong	Altered Expression	[404]
SDF4	OTQ7WFYW	Strong	Altered Expression	[275]
SERPINB1	OT5RDUFO	Strong	Altered Expression	[229]
SERPINB4	OT88LHZ8	Strong	Biomarker	[225]
SERPINB8	OT5T4Y5R	Strong	Biomarker	[405]
SETMAR	OTE2MIMZ	Strong	Biomarker	[403]
SH3BP4	OTVIRKW7	Strong	Biomarker	[406]
SHARPIN	OTU1J2KH	Strong	Biomarker	[407]
SHBG	OTPWU5IW	Strong	Genetic Variation	[52]
SLURP1	OT89YD2E	Strong	Biomarker	[408]
SLURP2	OTDWAJ2O	Strong	Biomarker	[352]
SMCP	OTXKY794	Strong	Genetic Variation	[355]
SNRNP70	OTP52YZ3	Strong	Genetic Variation	[409]
SOD3	OTIOZQAB	Strong	Altered Expression	[410]
SPATA2	OTOA45GL	Strong	Genetic Variation	[25]
SPINK5	OT61IIAO	Strong	Altered Expression	[411]
SPINK7	OTK3VOI3	Strong	Altered Expression	[412]
SPRED1	OTKX7P8G	Strong	Genetic Variation	[413]
SRF	OTW18FQN	Strong	Biomarker	[414]
STAT2	OTO9G2RZ	Strong	Biomarker	[89]
STAT4	OTAK3VFR	Strong	Altered Expression	[415]
STK40	OT4R325X	Strong	Biomarker	[416]
SUCO	OT3I9VO9	Strong	Biomarker	[369]
SUGP1	OT7W0EB8	Strong	Biomarker	[154]
TAB3	OT1ECMDL	Strong	Altered Expression	[253]
TAC1	OTM842YW	Strong	Biomarker	[62]
TACC2	OTW4M7HI	Strong	Biomarker	[294]
TAGAP	OTHJNNO2	Strong	Biomarker	[417]
TANK	OTZSGFIK	Strong	Biomarker	[195]
TBCC	OTBF0X8R	Strong	Genetic Variation	[418]
TCAIM	OTOBD7YO	Strong	Altered Expression	[419]
TCF19	OT7NKLF9	Strong	Biomarker	[420]
TEPSIN	OTJIVR84	Strong	Genetic Variation	[250]
TES	OTL8PP6V	Strong	Biomarker	[421]
TFIP11	OT7NVSWU	Strong	Biomarker	[160]
TIMP4	OT8A68SW	Strong	Biomarker	[153]
TLCD3B	OTM6EPUS	Strong	Altered Expression	[422]
TLE1	OT50MRZ1	Strong	Biomarker	[423]
TNFAIP8L2	OTII0RM0	Strong	Biomarker	[424]
TNFRSF6B	OTKAN9G7	Strong	Genetic Variation	[24]
TNFSF8	OTDYGDJ3	Strong	Biomarker	[425]
TNNT1	OT8PBOAR	Strong	Biomarker	[54]
TPM1	OTD73X6R	Strong	Posttranslational Modification	[426]
TPM2	OTA1L0P8	Strong	Altered Expression	[426]
TRAF3IP2	OTLLZERL	Strong	Genetic Variation	[427]
TRAIP	OTMPT9Y2	Strong	Biomarker	[351]
TREX1	OTQG7K12	Strong	Altered Expression	[428]
TREX2	OT5QAGJ4	Strong	Altered Expression	[429]
TRIM21	OTA4UJCF	Strong	Biomarker	[430]
TRIM32	OTJOV0PG	Strong	Altered Expression	[431]
TRMO	OTNJ7K9K	Strong	Altered Expression	[253]
TSC22D3	OT03UM03	Strong	Biomarker	[432]
TSPAN31	OT8WQ83R	Strong	Biomarker	[358]
TTC7A	OTDHLPQM	Strong	Genetic Variation	[433]
ADAMTSL5	OTQAGNQP	Definitive	Biomarker	[434]
CD79A	OTOJC8DV	Definitive	Biomarker	[435]
CSTA	OT1K68KE	Definitive	Biomarker	[229]
CXCL17	OTRCEVIZ	Definitive	Altered Expression	[436]
FLNB	OTPCOYL6	Definitive	Genetic Variation	[172]
KRT16	OTGA0EQN	Definitive	Biomarker	[437]
MTX1	OTLSDNZO	Definitive	Biomarker	[438]
MYDGF	OT9HRPL6	Definitive	Biomarker	[127]
NFKBIZ	OTU728KS	Definitive	Altered Expression	[439]
NXF1	OTEFHXG6	Definitive	Genetic Variation	[172]
PLAAT4	OTI66SAJ	Definitive	Biomarker	[440]
S100A1	OT1F2G4J	Definitive	Genetic Variation	[441]
S100A7A	OTNM8DCP	Definitive	Biomarker	[442]
SEC14L2	OTJST64D	Definitive	Genetic Variation	[172]
SOAT1	OTB4Y5RJ	Definitive	Biomarker	[443]
SYNGR1	OT0MBUK5	Definitive	Genetic Variation	[281]
TIMP3	OTDGQAD1	Definitive	Biomarker	[444]
TNXB	OTVBWAV5	Definitive	Biomarker	[445]

References

• [1] Atorvastatin FDA Label
• [2] Betamethasone FDA Label
• [3] Calcipotriol and psoriasis. Int J Dermatol. 1992 Aug;31(8):549-50.
• [4] Cortisone acetate FDA Label
• [5] Dexamethasone FDA Label
• [6] Erlotinib FDA Label
• [7] Hydrocortisone FDA Label
• [8] Methotrexate FDA Label
• [9] Methylprednisolone FDA Label
• [10] Co-delivery of methotrexate and nicotinamide by cerosomes for topical psoriasis treatment with enhanced efficacy. Int J Pharm. 2021 Aug 10;605:120826.
• [11] Prednisolone FDA Label
• [12] Prednisone FDA Label
• [13] Tazarotene FDA Label
• [14] Triamcinolone FDA Label
• [15] Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17;371(9625):1665-74.
• [16] Cosmeceutical Aptitudes of Niacinamide: A Review. Recent Adv Antiinfect Drug Discov. 2021;16(3):196-208.
• [17] A review of antibiotics and psoriasis: induction, exacerbation, and amelioration. Expert Rev Clin Pharmacol. 2019 Oct;12(10):981-989.
• [18] Pustular psoriasis. Cutis. 1993 Jan;51(1):29-32.
• [19] ClinicalTrials.gov (NCT05223868) A Phase 2b Multicenter, Randomized, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis. U.S.National Institutes of Health.
• [20] ClinicalTrials.gov (NCT05375955) A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE DOSE LEVELS OF PF-07038124 OINTMENT FOR 12 WEEKS IN PARTICIPANTS 12 YEARS AND OLDER AND WITH MILD-TO-MODERATE ATOPIC DERMATITIS OR MILD-TO-SEVERE PLAQUE PSORIASIS. U.S.National Institutes of Health.
• [21] Clinical pipeline report, company report or official report of JOHNSON & JOHNSON
• [22] Clinical pipeline report, company report or official report of Dyve Biosciences
• [23] Whole-exome SNP array identifies 15 new susceptibility loci for psoriasis.Nat Commun. 2015 Apr 9;6:6793. doi: 10.1038/ncomms7793.
• [24] Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci.Nat Genet. 2016 May;48(5):510-8. doi: 10.1038/ng.3528. Epub 2016 Mar 14.
• [25] Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms.Am J Hum Genet. 2015 Jan 8;96(1):104-20. doi: 10.1016/j.ajhg.2014.12.004.
• [26] Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis.Am J Clin Dermatol. 2019 Apr;20(2):295-306. doi: 10.1007/s40257-019-00435-9.
• [27] A genetic coding variant rs72474224 in GJB2 is associated with clinical features of psoriasis vulgaris in a Chinese Han population.Tissue Antigens. 2015 Aug;86(2):134-8. doi: 10.1111/tan.12595. Epub 2015 Jun 24.
• [28] Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants.Nat Commun. 2017 May 24;8:15382. doi: 10.1038/ncomms15382.
• [29] HLA Correlations with Clinical Phenotypes and Risk of Metabolic Comorbidities in Singapore Chinese Psoriasis Patients.Mol Diagn Ther. 2019 Dec;23(6):751-760. doi: 10.1007/s40291-019-00423-z.
• [30] Association between psoriasis vulgaris and MHC-DRB, -DQB genes as a contribution to disease diagnosis.Eur J Dermatol. 2005 May-Jun;15(3):159-63.
• [31] Trans-presentation of interleukin-15 by interleukin-15 receptor alpha is dispensable for the pathogenesis of autoimmune type 1 diabetes.Cell Mol Immunol. 2017 Jul;14(7):590-596. doi: 10.1038/cmi.2015.102. Epub 2016 Feb 8.
• [32] Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay.Sci Rep. 2019 Mar 26;9(1):5211. doi: 10.1038/s41598-019-41609-z.
• [33] IL-20 bone diseases involvement and therapeutic target potential.J Biomed Sci. 2018 Apr 24;25(1):38. doi: 10.1186/s12929-018-0439-z.
• [34] Clinical significance and immunobiology of IL-21 in autoimmunity.J Autoimmun. 2019 May;99:1-14. doi: 10.1016/j.jaut.2019.01.013. Epub 2019 Feb 14.
• [35] The PDE4 inhibitor CHF6001 modulates pro-inflammatory cytokines, chemokines and Th1- and Th17-polarizing cytokines in human dendritic cells.Biochem Pharmacol. 2019 May;163:371-380. doi: 10.1016/j.bcp.2019.03.006. Epub 2019 Mar 6.
• [36] Peroxisome Proliferator-Activated Receptor- Gene Polymorphism in Psoriasis and Its Relation to Obesity, Metabolic Syndrome, and Narrowband Ultraviolet B Response: A Case-Control Study in Egyptian Patients.Indian J Dermatol. 2019 May-Jun;64(3):192-200. doi: 10.4103/ijd.IJD_114_18.
• [37] Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.Am J Hum Genet. 2015 Dec 3;97(6):816-36. doi: 10.1016/j.ajhg.2015.10.019. Epub 2015 Nov 28.
• [38] Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-B and TLR7 pathways in mice.Biomed Pharmacother. 2019 Jan;109:1876-1883. doi: 10.1016/j.biopha.2018.10.062. Epub 2018 Nov 26.
• [39] Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases.Nat Med. 2015 Sep;21(9):1018-27. doi: 10.1038/nm.3933. Epub 2015 Aug 24.
• [40] Gene expression profiling reveals the role of RIG1 like receptor signaling in p53 dependent apoptosis induced by PUVA in keratinocytes.Cell Signal. 2016 Jan;28(1):25-33. doi: 10.1016/j.cellsig.2015.10.015. Epub 2015 Oct 27.
• [41] MiR-21 binding site SNP within ITGAM associated with psoriasis susceptibility in women.PLoS One. 2019 Jun 18;14(6):e0218323. doi: 10.1371/journal.pone.0218323. eCollection 2019.
• [42] Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to psoriasis in a Chinese population.J Renin Angiotensin Aldosterone Syst. 2014 Mar;15(1):39-43. doi: 10.1177/1470320313494433. Epub 2013 Jul 11.
• [43] The role of the Duffy antigen-related chemokine receptor in psoriasis vulgaris.Cytokine. 2002 Jun 21;18(6):329-33. doi: 10.1006/cyto.2002.0878.
• [44] Association of ADAM33 gene polymorphisms with psoriasis in a northeastern Chinese population.Mol Biol Rep. 2014 Jun;41(6):4001-5. doi: 10.1007/s11033-014-3268-5. Epub 2014 Feb 22.
• [45] Fine mapping and subphenotyping implicates ADRA1B gene variants in psoriasis susceptibility in a Chinese population.Epigenomics. 2019 Feb;11(4):455-467. doi: 10.2217/epi-2018-0131. Epub 2019 Feb 20.
• [46] Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-/IFN--induced inflammatory response in keratinocytes and T cell-derived IL-17.Pharmacol Res. 2018 Mar;129:443-452. doi: 10.1016/j.phrs.2017.11.012. Epub 2017 Nov 14.
• [47] Aryl hydrocarbon receptor polymorphisms are associated with dry skin phenotypes in Chinese patients with atopic dermatitis.Clin Exp Dermatol. 2019 Aug;44(6):613-619. doi: 10.1111/ced.13841. Epub 2018 Nov 29.
• [48] Ascorbic acid derivative DDH-1 ameliorates psoriasis-like skin lesions in mice by suppressing inflammatory cytokine expression.J Pharmacol Sci. 2018 Dec;138(4):284-288. doi: 10.1016/j.jphs.2018.11.002. Epub 2018 Nov 20.
• [49] MiR-125b-5p and miR-181b-5p inhibit keratinocyte proliferation in skin by targeting Akt3.Eur J Pharmacol. 2019 Nov 5;862:172659. doi: 10.1016/j.ejphar.2019.172659. Epub 2019 Sep 10.
• [50] Lack of association of ALOX12 and ALOX15B polymorphisms with psoriasis despite altered urinary excretion of 12(S)-hydroxyeicosatetraenoic acid.Br J Dermatol. 2015 Feb;172(2):337-44. doi: 10.1111/bjd.13225. Epub 2014 Nov 30.
• [51] mRNA and protein expression of the angiogenesis-related genes EDIL3, AMOT and ECM1 in mesenchymal stem cells in psoriatic dermis.Clin Exp Dermatol. 2016 Jul;41(5):533-40. doi: 10.1111/ced.12783. Epub 2015 Dec 8.
• [52] Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.J Am Acad Dermatol. 2017 Jun;76(6):1093-1102. doi: 10.1016/j.jaad.2016.12.014. Epub 2017 Mar 11.
• [53] Methylentetrahydrofolatereductase (rs1801133) polymorphism and psoriasis: contribution to oxidative stress, lipid peroxidation and correlation with vascular adhesion protein 1, preliminary report.J Eur Acad Dermatol Venereol. 2014 Sep;28(9):1192-8. doi: 10.1111/jdv.12262. Epub 2013 Sep 30.
• [54] Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis.Clin Drug Investig. 2017 Aug;37(8):775-785. doi: 10.1007/s40261-017-0533-0.
• [55] Apolipoprotein E gene polymorphism and serum lipid profile in Saudi patients with psoriasis.Dis Markers. 2014;2014:239645. doi: 10.1155/2014/239645. Epub 2014 Mar 23.
• [56] Yes-associated protein promotes the abnormal proliferation of psoriatic keratinocytes via an amphiregulin dependent pathway.Sci Rep. 2018 Oct 15;8(1):14513. doi: 10.1038/s41598-018-32522-y.
• [57] HIF-1-mediated BMP6 down-regulation leads to hyperproliferation and abnormal differentiation of keratinocytes in vitro.Exp Dermatol. 2018 Nov;27(11):1287-1293. doi: 10.1111/exd.13785. Epub 2018 Oct 9.
• [58] Nonclinical Safety and Toxicokinetics of MnTE-2-PyP (BMX-010), a Topical Agent in Phase 2 Trials for Psoriasis and Atopic Dermatitis.Int J Toxicol. 2019 Jul/Aug;38(4):291-302. doi: 10.1177/1091581819852325.
• [59] Antiviral gene expression in psoriasis.J Eur Acad Dermatol Venereol. 2015 Oct;29(10):1951-7. doi: 10.1111/jdv.13091. Epub 2015 Mar 23.
• [60] C5a/C5aR1 Pathway Is Critical for the Pathogenesis of Psoriasis.Front Immunol. 2019 Aug 7;10:1866. doi: 10.3389/fimmu.2019.01866. eCollection 2019.
• [61] Lack of association between leptin, leptin receptor, adiponectin gene polymorphisms and epicardial adipose tissue, abdominal visceral fat volume and atherosclerotic burden in psoriasis patients.Arch Physiol Biochem. 2015;121(3):103-8. doi: 10.3109/13813455.2015.1024136. Epub 2015 Jun 30.
• [62] Clearance of psoriasis after ischemic stroke.Cutis. 2019 Feb;103(2):74-76.
• [63] Human S100A7 Induces Mature Interleukin1 Expression by RAGE-p38 MAPK-Calpain1 Pathway in Psoriasis.PLoS One. 2017 Jan 6;12(1):e0169788. doi: 10.1371/journal.pone.0169788. eCollection 2017.
• [64] Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.Nat Genet. 2012 Dec;44(12):1341-8. doi: 10.1038/ng.2467. Epub 2012 Nov 11.
• [65] Th17 micro-milieu regulates NLRP1-dependent caspase-5 activity in skin autoinflammation.PLoS One. 2017 Apr 19;12(4):e0175153. doi: 10.1371/journal.pone.0175153. eCollection 2017.
• [66] Association of total oxidant status, total antioxidant status, and malondialdehyde and catalase levels with psoriasis: a systematic review and meta-analysis.Clin Rheumatol. 2019 Oct;38(10):2659-2671. doi: 10.1007/s10067-019-04676-1. Epub 2019 Jul 18.
• [67] Association of GA genotype of SNP rs4680 in COMT gene with psoriasis.Arch Dermatol Res. 2019 May;311(4):309-315. doi: 10.1007/s00403-019-01904-1. Epub 2019 Mar 6.
• [68] Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.J Dermatol. 2018 Jun;45(6):710-714. doi: 10.1111/1346-8138.14308. Epub 2018 Apr 14.
• [69] The CCL20 and CCR6 axis in psoriasis.Scand J Immunol. 2020 Mar;91(3):e12846. doi: 10.1111/sji.12846. Epub 2019 Nov 24.
• [70] Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris.Lab Invest. 2001 Mar;81(3):335-47. doi: 10.1038/labinvest.3780242.
• [71] A role for CCR5(+)CD4 T cells in cutaneous psoriasis and for CD103(+) CCR4(+) CD8 Teff cells in the associated systemic inflammation.J Autoimmun. 2016 Jun;70:80-90. doi: 10.1016/j.jaut.2016.03.019. Epub 2016 Apr 8.
• [72] Eczema in Psoriatico: An Important Differential Diagnosis Between Chronic Allergic Contact Dermatitis and Psoriasis in Palmoplantar Localization.Acta Derm Venereol. 2018 Jan 12;98(1):50-58. doi: 10.2340/00015555-2779.
• [73] CD200-CD200R1 signalling attenuates imiquimod-induced psoriatic inflammation by inhibiting the activation of skin inflammatory macrophages.Int Immunopharmacol. 2020 Jan;78:106046. doi: 10.1016/j.intimp.2019.106046. Epub 2019 Dec 10.
• [74] IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFN-producing T cells.Clin Immunol. 2017 Nov;184:33-41. doi: 10.1016/j.clim.2017.04.010. Epub 2017 Apr 28.
• [75] Superiority of a vitamin B(12)-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis.Int J Immunopathol Pharmacol. 2017 Dec;30(4):439-444. doi: 10.1177/0394632017736674. Epub 2017 Oct 19.
• [76] Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3.J Invest Dermatol. 2018 Feb;138(2):355-364. doi: 10.1016/j.jid.2017.08.038. Epub 2017 Sep 18.
• [77] Clinical Significance of Decreased Interleukin-35 Expression in Patients with Psoriasis.Microbiol Immunol. 2018 May 26. doi: 10.1111/1348-0421.12605. Online ahead of print.
• [78] Allelic distribution of complement components BF, C4A, C4B, and C3 in Psoriasis vulgaris.Immunol Lett. 2002 Mar 1;80(3):145-9. doi: 10.1016/s0165-2478(01)00317-0.
• [79] The discovery and optimization of a series of 2-aminobenzoxazole derivatives as ChemR23 inhibitors.Bioorg Med Chem. 2019 Nov 1;27(21):115091. doi: 10.1016/j.bmc.2019.115091. Epub 2019 Sep 6.
• [80] S100A7, Jab1, and p27(kip1) expression in psoriasis and S100A7 CRISPR-activated human keratinocyte cell line.J Cell Biochem. 2019 Mar;120(3):3384-3392. doi: 10.1002/jcb.27609. Epub 2018 Sep 11.
• [81] The association of PASI scores with CRH-R1 expression in patients with psoriasis.Arch Dermatol Res. 2012 Mar;304(2):127-32. doi: 10.1007/s00403-012-1218-4. Epub 2012 Feb 15.
• [82] Analysis of genetic variants of class II cytokine and their receptor genes in psoriasis patients of two ethnic groups from the Volga-Ural region of Russia.J Dermatol Sci. 2012 Oct;68(1):9-18. doi: 10.1016/j.jdermsci.2012.07.002. Epub 2012 Jul 16.
• [83] Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.Br J Dermatol. 2019 Jun;180(6):1352-1360. doi: 10.1111/bjd.17195. Epub 2018 Nov 2.
• [84] Cathepsin G cleaves and activates IL-36 and promotes the inflammation of psoriasis.Drug Des Devel Ther. 2019 Feb 8;13:581-588. doi: 10.2147/DDDT.S194765. eCollection 2019.
• [85] Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjgren syndrome.Arthritis Res Ther. 2019 Jul 18;21(1):175. doi: 10.1186/s13075-019-1955-2.
• [86] The cystatin M/E-controlled pathway of skin barrier formation: expression of its key components in psoriasis and atopic dermatitis.Br J Dermatol. 2009 Aug;161(2):253-64. doi: 10.1111/j.1365-2133.2009.09156.x. Epub 2009 Apr 24.
• [87] CX3CR1 deficiency attenuates imiquimod-induced psoriasis-like skin inflammation with decreased M1 macrophages.J Dermatol Sci. 2016 Jun;82(3):175-88. doi: 10.1016/j.jdermsci.2016.03.004. Epub 2016 Mar 4.
• [88] Elevated circulating levels of the interferon--induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset Still's disease.Sci Rep. 2017 Apr 24;7:46652. doi: 10.1038/srep46652.
• [89] STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes.PLoS One. 2017 May 4;12(5):e0176994. doi: 10.1371/journal.pone.0176994. eCollection 2017.
• [90] Circulating levels of chemokines in patients with psoriasis vulgaris and their association with disease severity: A case-control study from North India.Indian J Dermatol Venereol Leprol. 2019 Sep-Oct;85(5):567. doi: 10.4103/ijdvl.IJDVL_392_18.
• [91] The development and characterization of an in vitro model of psoriasis.J Invest Dermatol. 2004 Nov;123(5):892-901. doi: 10.1111/j.0022-202X.2004.23435.x.
• [92] CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders.J Clin Invest. 2016 Feb;126(2):667-80. doi: 10.1172/JCI81928. Epub 2016 Jan 19.
• [93] Ichthyosis molecular fingerprinting shows profound T(H)17 skewing and a unique barrier genomic signature.J Allergy Clin Immunol. 2019 Feb;143(2):604-618. doi: 10.1016/j.jaci.2018.03.021. Epub 2018 May 24.
• [94] MAPK Phosphatase-1 Deficiency Exacerbates the Severity of Imiquimod-Induced Psoriasiform Skin Disease.Front Immunol. 2018 Mar 21;9:569. doi: 10.3389/fimmu.2018.00569. eCollection 2018.
• [95] Protective effect of human endogenous retrovirus K dUTPase variants on psoriasis susceptibility.J Invest Dermatol. 2012 Jul;132(7):1833-40. doi: 10.1038/jid.2012.69. Epub 2012 Mar 22.
• [96] Effect of psoriasis activity and topical treatment on plasma epidermal growth factor (EGF) and its soluble receptor (sEGFR).J Dermatolog Treat. 2018 Mar;29(2):135-139. doi: 10.1080/09546634.2017.1343933. Epub 2017 Jul 6.
• [97] CCHCR1 is up-regulated in skin cancer and associated with EGFR expression.PLoS One. 2009 Jun 24;4(6):e6030. doi: 10.1371/journal.pone.0006030.
• [98] The association of ERAP1 and ERAP2 single nucleotide polymorphisms and their haplotypes with psoriasis vulgaris is dependent on the presence or absence of the HLA-C*06:02 allele and age at disease onset.Hum Immunol. 2018 Feb;79(2):109-116. doi: 10.1016/j.humimm.2017.11.010. Epub 2017 Nov 26.
• [99] Human immunodeficiency virus (HIV) transcripts identified in HIV-related psoriasis and Kaposi's sarcoma lesions.J Clin Invest. 1991 Jul;88(1):174-85. doi: 10.1172/JCI115275.
• [100] Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis.Arch Dermatol Res. 2019 Jul;311(5):389-397. doi: 10.1007/s00403-019-01917-w. Epub 2019 Apr 16.
• [101] Adipocyte Fatty Acid-Binding Protein as a Novel Marker of Psoriasis and Clinical Response to Acitretin.Lipids. 2019 Aug;54(8):445-452. doi: 10.1002/lipd.12173. Epub 2019 Jul 8.
• [102] Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque Psoriasis.J Immunol Res. 2015;2015:101879. doi: 10.1155/2015/101879. Epub 2015 Nov 3.
• [103] Decreased expression of G-protein-coupled receptors GPR43 and GPR109a in psoriatic skin can be restored by topical application of sodium butyrate.Arch Dermatol Res. 2018 Nov;310(9):751-758. doi: 10.1007/s00403-018-1865-1. Epub 2018 Sep 12.
• [104] FGF19 sustains the high proliferative ability of keratinocytes in psoriasis through the regulation of Wnt/GSK-3/-catenin signalling via FGFR4.Clin Exp Pharmacol Physiol. 2019 Aug;46(8):761-769. doi: 10.1111/1440-1681.13103. Epub 2019 Jun 3.
• [105] Serum vascular endothelial growth factor receptor 3 as a potential biomarker in psoriasis.Exp Dermatol. 2018 Sep;27(9):1053-1057. doi: 10.1111/exd.13727. Epub 2018 Jul 29.
• [106] Integrated analysis of gene expression profiles identifies transcription factors potentially involved in psoriasis pathogenesis.J Cell Biochem. 2019 Aug;120(8):12582-12594. doi: 10.1002/jcb.28525. Epub 2019 Mar 1.
• [107] Lymphocyte mass cytometry identifies a CD3-CD4+ cell subset with a potential role in psoriasis.JCI Insight. 2019 Mar 21;4(6):e125306. doi: 10.1172/jci.insight.125306. eCollection 2019 Mar 21.
• [108] Serum amyloid A, an acute phase protein, stimulates proliferative and proinflammatory responses of keratinocytes.Cell Prolif. 2017 Jun;50(3):e12320. doi: 10.1111/cpr.12320. Epub 2016 Dec 2.
• [109] PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.J Dermatolog Treat. 2018 Aug;29(5):481-486. doi: 10.1080/09546634.2017.1395805. Epub 2017 Nov 10.
• [110] The Presence of HLA-A Bw4-80I KIR Ligands Could Predict "Difficult-to-Treat" Psoriasis and Poor Response to Etanercept.Mol Diagn Ther. 2018 Aug;22(4):471-474. doi: 10.1007/s40291-018-0345-9.
• [111] Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms.Br J Dermatol. 2009 Feb;160(2):438-41. doi: 10.1111/j.1365-2133.2008.08898.x. Epub 2008 Oct 25.
• [112] MicroRNA-194 regulates keratinocyte proliferation and differentiation by targeting Grainyhead-like 2 in psoriasis.Pathol Res Pract. 2017 Feb;213(2):89-97. doi: 10.1016/j.prp.2016.11.020. Epub 2016 Dec 19.
• [113] Expression of epidermal N-methyl-D-aspartate receptors (NMDAR1) depends on formation of the granular layer--analysis in diseases with parakeratotic cornification.Arch Dermatol Res. 2004 Sep;296(4):157-62. doi: 10.1007/s00403-004-0505-0.
• [114] [HAX-1 protein: multifunctional factor involved in apoptosis, cell migration, endocytosis and mRNA transport].Postepy Biochem. 2007;53(3):218-27.
• [115] PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor.J Invest Dermatol. 2008 Jan;128(1):110-24. doi: 10.1038/sj.jid.5700943. Epub 2007 Jul 19.
• [116] Autoimmunitt gegen heterogenes nukleres Ribonukleoprotein A1 bei Psoriasispatienten und Korrelation mit dem Schweregrad der Erkrankung.J Dtsch Dermatol Ges. 2018 Sep;16(9):1103-1108. doi: 10.1111/ddg.13631_g.
• [117] Silencing of homeobox A5 gene in the stratum corneum of psoriasis.Exp Dermatol. 2017 Nov;26(11):1068-1074. doi: 10.1111/exd.13377. Epub 2017 Aug 15.
• [118] Genetic variations within the promotor region of the human histamine H4 receptor gene in psoriasis patients.Pharmacol Res. 2016 Dec;114:121-127. doi: 10.1016/j.phrs.2016.10.003. Epub 2016 Oct 7.
• [119] Expression of serotonergic receptors in psoriatic skin.Arch Dermatol Res. 2006 Aug;298(3):99-106. doi: 10.1007/s00403-006-0652-6. Epub 2006 Jun 23.
• [120] Association between the -1438A/G polymorphism of the serotonin 2A receptor gene and late-onset psoriasis in a Thai population.Genet Mol Res. 2010 Feb 2;9(1):208-14. doi: 10.4238/vol9-1gmr718.
• [121] Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation.J Invest Dermatol. 2016 Oct;136(10):1990-2002. doi: 10.1016/j.jid.2016.06.608. Epub 2016 Jun 29.
• [122] Sequencing-based approach identified three new susceptibility loci for psoriasis.Nat Commun. 2014 Jul 9;5:4331. doi: 10.1038/ncomms5331.
• [123] A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci.PLoS Genet. 2008 Mar 28;4(3):e1000041. doi: 10.1371/journal.pgen.1000041.
• [124] Up-regulation of interleukin-13 receptor alpha1 on human keratinocytes in the skin of psoriasis and atopic dermatitis.J Dermatol Sci. 2003 Oct;33(1):31-40. doi: 10.1016/s0923-1811(03)00148-8.
• [125] Interleukin-13 receptor in psoriatic keratinocytes: overexpression of the mRNA and underexpression of the protein.J Invest Dermatol. 2002 Nov;119(5):1114-20. doi: 10.1046/j.1523-1747.2002.19509.x.
• [126] Epidermal IL-15R acts as an endogenous antagonist of psoriasiform inflammation in mouse and man.J Exp Med. 2013 Sep 23;210(10):2105-17. doi: 10.1084/jem.20130291. Epub 2013 Sep 9.
• [127] The IL-23p19/EBI3 heterodimeric cytokine termed IL-39 remains a theoretical cytokine in man.Inflamm Res. 2019 Jun;68(6):423-426. doi: 10.1007/s00011-019-01235-x. Epub 2019 Apr 13.
• [128] IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease.Nat Immunol. 2019 Sep;20(9):1138-1149. doi: 10.1038/s41590-019-0467-1. Epub 2019 Aug 19.
• [129] The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis.Int J Mol Sci. 2019 Jul 5;20(13):3318. doi: 10.3390/ijms20133318.
• [130] IL-21 Induces an Imbalance of Th17/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients.Front Immunol. 2019 Aug 7;10:1865. doi: 10.3389/fimmu.2019.01865. eCollection 2019.
• [131] Interleukin-10 family cytokines pathway: genetic variants and psoriasis.Br J Dermatol. 2017 Jun;176(6):1577-1587. doi: 10.1111/bjd.15363. Epub 2017 Apr 21.
• [132] An Interleukin-25-Mediated Autoregulatory Circuit in Keratinocytes Plays a Pivotal Role in Psoriatic Skin Inflammation.Immunity. 2018 Apr 17;48(4):787-798.e4. doi: 10.1016/j.immuni.2018.03.019. Epub 2018 Apr 10.
• [133] Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases.Front Immunol. 2019 Jun 21;10:1383. doi: 10.3389/fimmu.2019.01383. eCollection 2019.
• [134] Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa.Br J Dermatol. 2017 Nov;177(5):1358-1366. doi: 10.1111/bjd.15458. Epub 2017 Sep 27.
• [135] Polymorphisms in IL36G gene are associated with plaque psoriasis.BMC Med Genet. 2019 Jan 11;20(1):10. doi: 10.1186/s12881-018-0742-2.
• [136] Multipolarity of cytokine axes in the pathogenesis of atopic dermatitis in terms of age, race, species, disease stage and biomarkers.Int Immunol. 2018 Aug 30;30(9):419-428. doi: 10.1093/intimm/dxy015.
• [137] Expression of B and T lymphocyte attenuator, retinoid-related orphan receptor gamma-isoform-t and interleukin 7 in psoriasis vulgaris.Australas J Dermatol. 2019 May;60(2):e132-e137. doi: 10.1111/ajd.12965. Epub 2019 Jan 22.
• [138] Anti-IL-12/IL-23p40 antibody ameliorates dermatitis and skin barrier dysfunction in mice with imiquimod-induced psoriasis-like dermatitis.Eur J Pharmacol. 2018 Jun 5;828:26-30. doi: 10.1016/j.ejphar.2018.03.018. Epub 2018 Mar 12.
• [139] JAK1/3 inhibition preserves epidermal morphology in full-thickness 3D skin models of atopic dermatitis and psoriasis.J Eur Acad Dermatol Venereol. 2019 Feb;33(2):367-375. doi: 10.1111/jdv.15301. Epub 2019 Jan 1.
• [140] Expression of bleomycin hydrolase in keratinization disorders.Arch Dermatol Res. 2012 Jan;304(1):31-8. doi: 10.1007/s00403-011-1180-6. Epub 2011 Oct 29.
• [141] Physiological and pathological roles of kallikrein-related peptidases in the epidermis.J Dermatol Sci. 2019 Aug;95(2):50-55. doi: 10.1016/j.jdermsci.2019.06.007. Epub 2019 Jun 27.
• [142] Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy.Br J Dermatol. 2007 May;156(5):875-83. doi: 10.1111/j.1365-2133.2006.07743.x.
• [143] Lysosome Alterations in the Human Epithelial Cell Line HaCaT and Skin Specimens: Relevance to Psoriasis.Int J Mol Sci. 2019 May 7;20(9):2255. doi: 10.3390/ijms20092255.
• [144] Polymorphisms in HLA-related genes and psoriasis heredity in patients with psoriasis.Int J Dermatol. 2013 Aug;52(8):960-5. doi: 10.1111/ijd.12213. Epub 2013 Jul 8.
• [145] MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation.J Clin Invest. 2018 Jun 1;128(6):2551-2568. doi: 10.1172/JCI97426. Epub 2018 May 14.
• [146] Resolved psoriasis lesions retain expression of a subset of disease-related genes.J Invest Dermatol. 2011 Feb;131(2):391-400. doi: 10.1038/jid.2010.280. Epub 2010 Sep 23.
• [147] CARD14-Mediated Activation of Paracaspase MALT1 in Keratinocytes: Implications for Psoriasis.J Invest Dermatol. 2017 Mar;137(3):569-575. doi: 10.1016/j.jid.2016.09.031. Epub 2016 Dec 8.
• [148] Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2.J Immunol. 2006 Feb 1;176(3):1431-8. doi: 10.4049/jimmunol.176.3.1431.
• [149] Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis.J Dermatol Sci. 2018 Feb;89(2):136-145. doi: 10.1016/j.jdermsci.2017.11.003. Epub 2017 Nov 20.
• [150] Glutathione S-transferase M1 (GSTM1) genotype but not GSTT1 or MC1R genotype influences erythemal sensitivity to narrow band (TL-01) UVB phototherapy.Pharmacogenet Genomics. 2011 Apr;21(4):217-24. doi: 10.1097/FPC.0b013e32833efb36.
• [151] Gene expression analysis of the corticotrophin-releasing hormone-proopiomelanocortin system in psoriasis skin biopsies.Acta Derm Venereol. 2013 Jul 6;93(4):400-5. doi: 10.2340/00015555-1524.
• [152] Immunohistochemical staining of palisading basal cells in Bowen's disease and basal involvement in actinic keratosis: contrasting staining patterns suggest different cells of origin.Am J Dermatopathol. 2008 Apr;30(2):123-6. doi: 10.1097/DAD.0b013e3181658062.
• [153] Differences in Osteoimmunological Biomarkers Predictive of Psoriatic Arthritis among a Large Italian Cohort of Psoriatic Patients.Int J Mol Sci. 2019 Nov 10;20(22):5617. doi: 10.3390/ijms20225617.
• [154] Kidney involvement in psoriasis: a case-control study from China.Int Urol Nephrol. 2017 Nov;49(11):1999-2003. doi: 10.1007/s11255-017-1692-x. Epub 2017 Sep 22.
• [155] Wnt5a exhibits layer-specific expression in adult skin, is upregulated in psoriasis, and synergizes with type 1 interferon.PLoS One. 2009;4(4):e5354. doi: 10.1371/journal.pone.0005354. Epub 2009 Apr 28.
• [156] Identification of a Single Nucleotide Polymorphism in NFKBIA with Different Effects on Psoriatic Arthritis and Cutaneous Psoriasis in China.Acta Derm Venereol. 2019 Jan 1;99(1):84-88. doi: 10.2340/00015555-3027.
• [157] Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.Oncol Res. 2017 Sep 21;25(8):1223-1229. doi: 10.3727/096504017X14876245096439. Epub 2017 Mar 2.
• [158] Mapping and identifying genes for asthma and psoriasis.Philos Trans R Soc Lond B Biol Sci. 2005 Aug 29;360(1460):1551-61. doi: 10.1098/rstb.2005.1684.
• [159] Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis.J Transl Med. 2013 Aug 22;11:194. doi: 10.1186/1479-5876-11-194.
• [160] Serum neurotensin (NT) is increased in psoriasis and NT induces vascular endothelial growth factor release from human mast cells.Br J Dermatol. 2012 Jun;166(6):1349-52. doi: 10.1111/j.1365-2133.2012.10843.x. Epub 2012 May 14.
• [161] Association Between Soluble Lectinlike Oxidized Low-Density Lipoprotein Receptor-1 and Coronary Artery Disease in Psoriasis.JAMA Dermatol. 2020 Feb 1;156(2):151-157. doi: 10.1001/jamadermatol.2019.3595.
• [162] Opioid Receptors in Psoriatic Skin: Relationship with Itch.Acta Derm Venereol. 2017 May 8;97(5):564-570. doi: 10.2340/00015555-2595.
• [163] The prevalence of ADH1B and OPRM1 alleles predisposing for alcohol consumption are increased in the Hungarian psoriasis population.Arch Dermatol Res. 2019 Aug;311(6):435-442. doi: 10.1007/s00403-019-01915-y. Epub 2019 Apr 22.
• [164] Effect of white mange mixture in a murine model of psoriasis.Exp Ther Med. 2019 Aug;18(2):881-887. doi: 10.3892/etm.2019.7641. Epub 2019 Jun 4.
• [165] Gene polymorphisms as predictors of response to biological therapies in psoriasis patients.Pharmacol Res. 2016 Nov;113(Pt A):71-80. doi: 10.1016/j.phrs.2016.07.020. Epub 2016 Aug 12.
• [166] Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.Cell Signal. 2016 Jul;28(7):753-63. doi: 10.1016/j.cellsig.2016.01.007. Epub 2016 Jan 22.
• [167] Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?.Curr Pharm Des. 2006;12(25):3207-20. doi: 10.2174/138161206778194123.
• [168] Glucose transporter-1 (GLUT-1) expression in psoriasis: correlation with disease severity.Int J Dermatol. 2018 Aug;57(8):943-951. doi: 10.1111/ijd.14037. Epub 2018 May 24.
• [169] Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis.J Dermatolog Treat. 2020 Aug;31(5):524-530. doi: 10.1080/09546634.2019.1606887. Epub 2019 May 15.
• [170] Suprabasal overexpression of the hsRPB7 gene in psoriatic epidermis as identified by a reverse transcriptase-polymerase chain reaction differential display model comparing psoriasis plaque tissue with peritonsillar mucosa.Am J Pathol. 2001 Feb;158(2):367-72. doi: 10.1016/s0002-9440(10)63978-8.
• [171] Activation of keratinocyte protein kinase C zeta in psoriasis plaques.J Invest Dermatol. 2008 Sep;128(9):2190-7. doi: 10.1038/jid.2008.81. Epub 2008 Apr 3.
• [172] Strong associations of psoriasis with antigen processing LMP and transport genes TAP differ by gender and phenotype.Genes Immun. 2007 Sep;8(6):513-7. doi: 10.1038/sj.gene.6364404. Epub 2007 Jun 21.
• [173] Associations between PTPN2 gene polymorphisms and psoriasis in Northeastern China.Gene. 2019 Jan 10;681:73-79. doi: 10.1016/j.gene.2018.09.047. Epub 2018 Sep 26.
• [174] The association of polymorphisms of the vitamin D receptor gene with psoriasis in the Han population of northeastern China.J Dermatol Sci. 2014 Jan;73(1):63-6. doi: 10.1016/j.jdermsci.2013.08.014. Epub 2013 Sep 7.
• [175] Ginsenoside compound K ameliorates imiquimod-induced psoriasis-like dermatitis through inhibiting REG3A/RegIII expression in keratinocytes.Biochem Biophys Res Commun. 2019 Aug 6;515(4):665-671. doi: 10.1016/j.bbrc.2019.06.007. Epub 2019 Jun 7.
• [176] Aliskiren: Preclinical evidence for the treatment of hyperproliferative skin disorders.Biomed Pharmacother. 2018 Aug;104:151-157. doi: 10.1016/j.biopha.2018.03.157. Epub 2018 May 14.
• [177] Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation.Cold Spring Harb Perspect Biol. 2020 Mar 2;12(3):a036368. doi: 10.1101/cshperspect.a036368.
• [178] The E3 Ubiquitin Ligase RNF7 Negatively Regulates CARD14/CARMA2sh Signaling.Int J Mol Sci. 2017 Dec 1;18(12):2581. doi: 10.3390/ijms18122581.
• [179] Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines.J Invest Dermatol. 2006 Aug;126(8):1784-91. doi: 10.1038/sj.jid.5700252. Epub 2006 Mar 16.
• [180] Downregulation of RUNX3 moderates the frequency of Th17 and Th22 cells in patients with psoriasis.Mol Med Rep. 2016 Jun;13(6):4606-12. doi: 10.3892/mmr.2016.5108. Epub 2016 Apr 12.
• [181] Psoriasis, sacro-iliitis and peripheral arthritis occurring in patients with the same HLA haplotype. A preliminary family report and a hypothetical explanation of the interaction between MHS products.Tissue Antigens. 1976 Aug;8(2):131-8.
• [182] Reduced stratum corneum acylceramides in autosomal recessive congenital ichthyosis with a NIPAL4 mutation.J Dermatol Sci. 2020 Jan;97(1):50-56. doi: 10.1016/j.jdermsci.2019.12.001. Epub 2019 Dec 4.
• [183] Study of serum levels and skin expression of S100B protein in psoriasis.An Bras Dermatol. 2017 May-Jun;92(3):323-328. doi: 10.1590/abd1806-4841.20175038.
• [184] Macrophage S1PR1 Signaling Alters Angiogenesis and Lymphangiogenesis During Skin Inflammation.Cells. 2019 Jul 28;8(8):785. doi: 10.3390/cells8080785.
• [185] Interleukin-17A-induced production of acute serum amyloid A by keratinocytes contributes to psoriasis pathogenesis.PLoS One. 2017 Jul 14;12(7):e0181486. doi: 10.1371/journal.pone.0181486. eCollection 2017.
• [186] Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis.JCI Insight. 2018 Jan 11;3(1):e97179. doi: 10.1172/jci.insight.97179. eCollection 2018 Jan 11.
• [187] Long-term treatment of chronic plaque psoriasis with biological drugs can control platelet activation: targeting the bridge between inflammation and atherothrombosis.Postepy Dermatol Alergol. 2017 Apr;34(2):131-137. doi: 10.5114/ada.2017.67077. Epub 2017 Apr 13.
• [188] Follow-up analysis of circulating mononuclear cell CLA expression in patients with psoriasis.J Dermatol Sci. 2005 Aug;39(2):131-3. doi: 10.1016/j.jdermsci.2005.04.005.
• [189] A Preliminary Study of the Effect of Semaphorin 3A and Acitretin on the Proliferation, Migration, and Apoptosis of HaCaT Cells.Indian J Dermatol. 2019 May-Jun;64(3):250. doi: 10.4103/ijd.IJD_179_18.
• [190] CD100-Plexin-B2 Promotes the Inflammation in Psoriasis by Activating NF-B and the Inflammasome inKeratinocytes.J Invest Dermatol. 2018 Feb;138(2):375-383. doi: 10.1016/j.jid.2017.09.005. Epub 2017 Sep 18.
• [191] Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients.Sci Rep. 2018 Sep 4;8(1):13182. doi: 10.1038/s41598-018-31352-2.
• [192] Inhibiting Sphingosine Kinase 2 Derived-sphingosine-1-phosphate Ameliorates Psoriasis-like Skin Disease via Blocking Th17 Differentiation of Nave CD4 T Lymphocytes in Mice.Acta Derm Venereol. 2019 May 1;99(6):594-601. doi: 10.2340/00015555-3160.
• [193] Expression of pro-angiogenic genes in mesenchymal stem cells derived from dermis of patients with psoriasis.Int J Dermatol. 2016 May;55(5):e280-8. doi: 10.1111/ijd.13197. Epub 2016 Jan 8.
• [194] Dermal mesenchymal stem cells: a resource of migration-associated function in psoriasis?.Stem Cell Res Ther. 2019 Feb 13;10(1):54. doi: 10.1186/s13287-019-1159-3.
• [195] CARD14/CARMA2sh and TANK differentially regulate poly(I:C)-induced inflammatory reaction in keratinocytes.J Cell Physiol. 2020 Mar;235(3):1895-1902. doi: 10.1002/jcp.29161. Epub 2019 Sep 4.
• [196] Xenotransplantation Model of Psoriasis.Methods Mol Biol. 2017;1559:83-90. doi: 10.1007/978-1-4939-6786-5_7.
• [197] Evaluation of plasma levels of tissue factor and tissue factor pathway inhibitor in patients with psoriasis.Postepy Dermatol Alergol. 2019 Aug;36(4):442-448. doi: 10.5114/ada.2019.87447. Epub 2019 Aug 30.
• [198] Activation of ribosomal protein S6 kinase in psoriatic lesions and cultured human keratinocytes by epidermal growth factor receptor ligands.J Invest Dermatol. 1997 Jan;108(1):98-102. doi: 10.1111/1523-1747.ep12285647.
• [199] Keratinocyte transglutaminase expression varies in squamous cell carcinomas.J Invest Dermatol. 1994 Apr;102(4):462-9. doi: 10.1111/1523-1747.ep12373021.
• [200] The polymorphism rs4696480 in the TLR2 gene is associated with psoriasis patients in the Turkish population.Immunol Lett. 2019 Jul;211:28-32. doi: 10.1016/j.imlet.2019.05.008. Epub 2019 May 21.
• [201] Activation of the HMGB1TLR4NFB pathway may occur in patients with atopic eczema.Mol Med Rep. 2017 Sep;16(3):2714-2720. doi: 10.3892/mmr.2017.6942. Epub 2017 Jul 6.
• [202] Staphylococcal -toxin induces a functional upregulation of TLR-2 on human peripheral blood monocytes.Exp Dermatol. 2015 May;24(5):381-3. doi: 10.1111/exd.12674.
• [203] Acetyl-11-keto--boswellic acid inhibits the secretion of cytokines by dendritic cells via the TLR7/8 pathway in an imiquimod-induced psoriasis mouse model and in vitro.Life Sci. 2018 Aug 15;207:90-104. doi: 10.1016/j.lfs.2018.05.044. Epub 2018 May 31.
• [204] Toll-like receptor 9 promoter polymorphism as a predictive factor of narrow-band UVB phototherapy response in patients with psoriasis.Photodermatol Photoimmunol Photomed. 2015 Mar;31(2):98-103. doi: 10.1111/phpp.12160. Epub 2015 Jan 19.
• [205] B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies.Endocrinology. 2012 Feb;153(2):739-49. doi: 10.1210/en.2011-1504. Epub 2011 Dec 13.
• [206] Differential expression of BAFF and its receptors in discoid lupus erythematosus patients.J Dermatol Sci. 2014 Mar;73(3):216-24. doi: 10.1016/j.jdermsci.2013.11.007. Epub 2013 Nov 16.
• [207] TWEAK mediates inflammation in experimental atopic dermatitis and psoriasis.Nat Commun. 2017 May 22;8:15395. doi: 10.1038/ncomms15395.
• [208] Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling.Hum Mol Genet. 2017 Nov 1;26(21):4301-4313. doi: 10.1093/hmg/ddx328.
• [209] TRIM27 promotes IL-6-induced proliferation and inflammation factor production by activating STAT3 signaling in HaCaT cells.Am J Physiol Cell Physiol. 2020 Feb 1;318(2):C272-C281. doi: 10.1152/ajpcell.00314.2019. Epub 2019 Nov 20.
• [210] TRPA1 Acts in a Protective Manner in Imiquimod-Induced Psoriasiform Dermatitis in Mice.J Invest Dermatol. 2018 Aug;138(8):1774-1784. doi: 10.1016/j.jid.2018.02.040. Epub 2018 Mar 14.
• [211] Hypoxia inhibits TNF--induced TSLP expression in keratinocytes.PLoS One. 2019 Nov 4;14(11):e0224705. doi: 10.1371/journal.pone.0224705. eCollection 2019.
• [212] ITK and RLK Inhibitor PRN694 Improves Skin Disease in Two Mouse Models of Psoriasis.J Invest Dermatol. 2018 Apr;138(4):864-871. doi: 10.1016/j.jid.2017.10.029. Epub 2017 Nov 10.
• [213] Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).Expert Opin Ther Pat. 2019 Feb;29(2):137-149. doi: 10.1080/13543776.2019.1567713. Epub 2019 Jan 22.
• [214] Ubiquitin-specific peptidase 2 as a potential link between microRNA-125b and psoriasis.Br J Dermatol. 2017 Mar;176(3):723-731. doi: 10.1111/bjd.14916. Epub 2016 Dec 30.
• [215] Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis.Arthritis Care Res (Hoboken). 2020 Jun;72(6):806-813. doi: 10.1002/acr.23905. Epub 2020 May 15.
• [216] Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.Bioorg Med Chem. 2018 Feb 15;26(4):945-956. doi: 10.1016/j.bmc.2017.07.054. Epub 2017 Aug 2.
• [217] In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine.Theranostics. 2019 Apr 13;9(9):2475-2488. doi: 10.7150/thno.31144. eCollection 2019.
• [218] Mannan-binding lectin promotes keratinocyte to produce CXCL1 and enhances neutrophil infiltration at the early stages of psoriasis.Exp Dermatol. 2019 Sep;28(9):1017-1024. doi: 10.1111/exd.13995. Epub 2019 Aug 13.
• [219] FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNF inhibitors.Pharmacogenomics J. 2017 Jun;17(3):237-241. doi: 10.1038/tpj.2016.16. Epub 2016 Apr 5.
• [220] FGF-7 facilitates the process of psoriasis by inducing TNF- expression in HaCaT cells.Acta Biochim Biophys Sin (Shanghai). 2019 Sep 6;51(10):1056-1063. doi: 10.1093/abbs/gmz095.
• [221] AP-1 Expression and its Clinical Relevance in Immune Disorders and Cancer.Am J Med Sci. 2017 May;353(5):474-483. doi: 10.1016/j.amjms.2017.01.019. Epub 2017 Feb 1.
• [222] Identification of unique proteomic signatures in allergic and non-allergic skin disease.Clin Exp Allergy. 2017 Nov;47(11):1456-1467. doi: 10.1111/cea.12979. Epub 2017 Aug 11.
• [223] Integrative analyses reveal biological pathways and key genes in psoriasis.Br J Dermatol. 2017 Nov;177(5):1349-1357. doi: 10.1111/bjd.15682. Epub 2017 Oct 25.
• [224] TNF-alpha inhibition could reduce biomarkers of endothelial dysfunction in patients with moderate to severe psoriasis: A 52-week echo-Doppler based quasi-experimental study.Med Clin (Barc). 2018 Jun 22;150(12):465-468. doi: 10.1016/j.medcli.2017.08.014. Epub 2017 Oct 28.
• [225] Squamous Cell Carcinoma Antigen 2 (SCCA2, SERPINB4): An Emerging Biomarker for Skin Inflammatory Diseases.Int J Mol Sci. 2018 Apr 6;19(4):1102. doi: 10.3390/ijms19041102.
• [226] The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients.Arch Dermatol Res. 2015 Jul;307(5):405-12. doi: 10.1007/s00403-014-1533-z. Epub 2014 Dec 24.
• [227] Differential effects of Wnt5a on the proliferation, differentiation and inflammatory response of keratinocytes.Mol Med Rep. 2018 Mar;17(3):4043-4048. doi: 10.3892/mmr.2017.8358. Epub 2017 Dec 27.
• [228] Systematic linkage disequilibrium analysis of SLC12A8 at PSORS5 confirms a role in susceptibility to psoriasis vulgaris.J Invest Dermatol. 2005 Nov;125(5):906-12. doi: 10.1111/j.0022-202X.2005.23847.x.
• [229] Proteomics of skin proteins in psoriasis: from discovery and verification in a mouse model to confirmation in humans.Mol Cell Proteomics. 2015 Jan;14(1):109-19. doi: 10.1074/mcp.M114.042242. Epub 2014 Oct 28.
• [230] Major Role for TRPV1 and InsP3R inPAR2-Elicited Inflammatory MediatorProduction in Differentiated Human Keratinocytes.J Invest Dermatol. 2018 Jul;138(7):1564-1572. doi: 10.1016/j.jid.2018.01.034. Epub 2018 Feb 17.
• [231] Investigation of the chromosome 17q25 PSORS2 locus in atopic dermatitis.J Invest Dermatol. 2006 Mar;126(3):603-6. doi: 10.1038/sj.jid.5700108.
• [232] Polymorphism of glutathione S-transferase M1 and T1 genes and susceptibility to psoriasis disease: A study from North India.Indian J Dermatol Venereol Leprol. 2018 Jan-Feb;84(1):39-44. doi: 10.4103/ijdvl.IJDVL_1128_16.
• [233] Matrix metalloproteinase-2 promoter variability in psoriasis.Arch Dermatol Res. 2009 Jul;301(6):467-73. doi: 10.1007/s00403-009-0947-5. Epub 2009 Apr 10.
• [234] Combined Transcriptomic Analysis Revealed AKR1B10 Played an Important Role in Psoriasis through the Dysregulated Lipid Pathway and Overproliferation of Keratinocyte.Biomed Res Int. 2017;2017:8717369. doi: 10.1155/2017/8717369. Epub 2017 Oct 24.
• [235] Mast cells express CYP27A1 and CYP27B1 in epithelial skin cancers and psoriasis.Eur J Dermatol. 2015 Nov-Dec;25(6):548-55. doi: 10.1684/ejd.2015.2645.
• [236] Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet. 2003 Apr 19;361(9366):1336-43.
• [237] Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease.JAMA Neurol. 2016 Jun 1;73(6):691-7. doi: 10.1001/jamaneurol.2016.0150.
• [238] The role of sterol-C4-methyl oxidase in epidermal biology.Biochim Biophys Acta. 2014 Mar;1841(3):331-5. doi: 10.1016/j.bbalip.2013.10.009. Epub 2013 Oct 18.
• [239] A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis.Nat Genet. 2003 Dec;35(4):349-56. doi: 10.1038/ng1268. Epub 2003 Nov 9.
• [240] A Controlled Study of the Feasibility and Efficacy of a Cloud-Based Interactive Management Program Between Patients with Psoriasis and Physicians.Med Sci Monit. 2019 Feb 4;25:970-976. doi: 10.12659/MSM.913304.
• [241] Influence of calcium on the proteolytic degradation of the calmodulin-like skin protein (calmodulin-like protein 5) in psoriatic epidermis.Exp Dermatol. 2006 Jun;15(6):469-77. doi: 10.1111/j.1600-0625.2006.00433.x.
• [242] An association study of 22 candidate genes in psoriasis families reveals shared genetic factors with other autoimmune and skin disorders.J Invest Dermatol. 2009 Nov;129(11):2637-45. doi: 10.1038/jid.2009.157. Epub 2009 Jun 25.
• [243] Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci.Nat Commun. 2015 May 5;6:7001. doi: 10.1038/ncomms8001.
• [244] Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility.Nat Commun. 2015 Apr 23;6:6916. doi: 10.1038/ncomms7916.
• [245] Genome-wide association study of psoriasis in an Egyptian population.Exp Dermatol. 2019 May;28(5):623-627. doi: 10.1111/exd.13926.
• [246] Decreased A-to-I RNA editing as a source of keratinocytes' dsRNA in psoriasis.RNA. 2018 Jun;24(6):828-840. doi: 10.1261/rna.064659.117. Epub 2018 Mar 28.
• [247] A potential association between psoriasin to rs4819554 of IL-17RA gene polymorphism in psoriasis Egyptian patients.Arch Dermatol Res. 2020 May;312(4):273-281. doi: 10.1007/s00403-019-02011-x. Epub 2019 Nov 19.
• [248] Relationship between human leukocyte antigen DRB1 and psoriasis in Iraqi patients.Saudi Med J. 2018 Sep;39(9):886-890. doi: 10.15537/smj.2018.9.23156.
• [249] Regulation of RANKL-induced osteoclastogenesis by RING finger protein RNF114.J Orthop Res. 2018 Jan;36(1):159-166. doi: 10.1002/jor.23654. Epub 2017 Jul 31.
• [250] A promoter sequence variant of ZNF750 is linked with familial psoriasis.J Invest Dermatol. 2008 Jul;128(7):1662-8. doi: 10.1038/jid.2008.1. Epub 2008 Feb 7.
• [251] Chronic hand eczema: is IL-36 helpful in diagnosis and classification?.G Ital Dermatol Venereol. 2017 Dec;152(6):578-585. doi: 10.23736/S0392-0488.16.05312-8. Epub 2016 Apr 1.
• [252] MicroRNA-146 and cell trauma down-regulate expression of the psoriasis-associated atypical chemokine receptor ACKR2.J Biol Chem. 2018 Feb 23;293(8):3003-3012. doi: 10.1074/jbc.M117.809780. Epub 2017 Dec 26.
• [253] Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ.J Invest Dermatol. 1991 Jul;97(1):73-9. doi: 10.1111/1523-1747.ep12478128.
• [254] EFLA 945 restricts AIM2 inflammasome activation by preventing DNA entry for psoriasis treatment.Cytokine. 2020 Mar;127:154951. doi: 10.1016/j.cyto.2019.154951. Epub 2019 Dec 11.
• [255] Upregulation of ANGPTL6 in mouse keratinocytes enhances susceptibility to psoriasis.Sci Rep. 2016 Oct 4;6:34690. doi: 10.1038/srep34690.
• [256] Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?.Ther Clin Risk Manag. 2019 Jul 5;15:831-837. doi: 10.2147/TCRM.S197633. eCollection 2019.
• [257] Abnormality of RUNX1 signal transduction in psoriatic CD34+ bone marrow cells.Br J Dermatol. 2011 May;164(5):1043-51. doi: 10.1111/j.1365-2133.2010.10192.x.
• [258] Proteomic plasma profile of psoriatic patients.J Pharm Biomed Anal. 2018 Jun 5;155:185-193. doi: 10.1016/j.jpba.2018.03.068. Epub 2018 Apr 4.
• [259] BCAP 31 expression and promoter demethylation in psoriasis.Asian Pac J Allergy Immunol. 2017 Jun;35(2):86-90. doi: 10.12932/AP0818.
• [260] Bcl-3 induced by IL-22 via STAT3 activation acts as a potentiator of psoriasis-related gene expression in epidermal keratinocytes.Eur J Immunol. 2018 Jan;48(1):168-179. doi: 10.1002/eji.201747017. Epub 2017 Nov 20.
• [261] Correlation analysis of the HLA-DPB1*05:01 and BTNL2 genes within the histocompatibility complex region with a clinical phenotype of psoriasis vulgaris in the Chinese Han population.J Gene Med. 2017 Sep;19(9-10). doi: 10.1002/jgm.2961. Epub 2017 Sep 19.
• [262] Increased TrCP are associated with imiquimod-induced psoriasis-like skin inflammation in mice via NF-B signaling pathway.Gene. 2016 Oct 30;592(1):164-171. doi: 10.1016/j.gene.2016.07.066. Epub 2016 Jul 28.
• [263] A novel splicing variant of CADM2 as a protective transcript of psoriasis.Biochem Biophys Res Commun. 2011 Sep 9;412(4):626-32. doi: 10.1016/j.bbrc.2011.08.013. Epub 2011 Aug 11.
• [264] RETRACTED: NFKB1 mediates Th1/Th17 activation in the pathogenesis of psoriasis.Cell Immunol. 2018 Sep;331:16-21. doi: 10.1016/j.cellimm.2018.04.016. Epub 2018 May 2.
• [265] Inhibition of CCR7/CCL19 axis in lesional skin is a critical event for clinical remission induced by TNF blockade in patients with psoriasis.Am J Pathol. 2013 Aug;183(2):413-21. doi: 10.1016/j.ajpath.2013.04.021. Epub 2013 May 31.
• [266] CCL7 contributes to the TNF-alpha-dependent inflammation of lesional psoriatic skin.Exp Dermatol. 2015 Jul;24(7):522-8. doi: 10.1111/exd.12709. Epub 2015 May 4.
• [267] c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies.Nat Immunol. 2019 Aug;20(8):992-1003. doi: 10.1038/s41590-019-0423-0. Epub 2019 Jul 1.
• [268] A molecular basis of human T cell receptor autoreactivity toward self-phospholipids.Sci Immunol. 2017 Oct 20;2(16):eaao1384. doi: 10.1126/sciimmunol.aao1384.
• [269] A central role for transcription factor C/EBP-beta in regulating CD1d gene expression in human keratinocytes.J Immunol. 2009 Aug 1;183(3):1657-66. doi: 10.4049/jimmunol.0900057. Epub 2009 Jul 10.
• [270] Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab.J Dermatolog Treat. 2019 Mar;30(2):123-128. doi: 10.1080/09546634.2018.1476649. Epub 2018 May 25.
• [271] Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis. Br J Dermatol. 2017 May;176(5):1288-1296.
• [272] Psoriasis and Pro-angiogenetic Factor CD93: Gene Expression and Association with Gene Polymorphism Suggests a Role in Disease Pathogenesis.Acta Derm Venereol. 2017 Aug 31;97(8):916-921. doi: 10.2340/00015555-2682.
• [273] Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes.Cell Death Dis. 2019 Mar 20;10(4):274. doi: 10.1038/s41419-019-1510-8.
• [274] Shikonin induces apoptosis and suppresses growth in keratinocytes via CEBP- upregulation.Int Immunopharmacol. 2019 Jul;72:511-521. doi: 10.1016/j.intimp.2019.04.047. Epub 2019 May 7.
• [275] Human S100A15 splice variants are differentially expressed in inflammatory skin diseases and regulated through Th1 cytokines and calcium.Exp Dermatol. 2007 Aug;16(8):685-91. doi: 10.1111/j.1600-0625.2007.00587.x.
• [276] C19, a C-terminal peptide of CKLF1, decreases inflammation and proliferation of dermal capillaries in psoriasis.Sci Rep. 2017 Oct 24;7(1):13890. doi: 10.1038/s41598-017-13799-x.
• [277] Role of nitric oxide-scavenging activity of Karanjin and Pongapin in the treatment of Psoriasis.3 Biotech. 2018 Aug;8(8):338. doi: 10.1007/s13205-018-1337-5. Epub 2018 Jul 25.
• [278] Claudin-3 - a new intestinal integrity marker in patients with psoriasis: association with disease severity.J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1907-1912. doi: 10.1111/jdv.15700. Epub 2019 Jun 19.
• [279] A comprehensive analysis of pattern recognition receptors in normal and inflamed human epidermis: upregulation of dectin-1 in psoriasis.J Invest Dermatol. 2010 Nov;130(11):2611-20. doi: 10.1038/jid.2010.196. Epub 2010 Jul 15.
• [280] Treatment modifying factors of biologics for psoriatic arthritis: a systematic review and Bayesian meta-regression.Clin Exp Rheumatol. 2017 Jul-Aug;35(4):681-688. Epub 2017 Jan 15.
• [281] Allele-specific transcription factor binding to common and rare variants associated with disease and gene expression.Hum Genet. 2016 May;135(5):485-497. doi: 10.1007/s00439-016-1654-x. Epub 2016 Mar 18.
• [282] Dermatology Life Quality Index and disease coping strategies in psoriasis patients.Postepy Dermatol Alergol. 2019 Aug;36(4):419-424. doi: 10.5114/ada.2018.75810. Epub 2019 Aug 30.
• [283] Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis.Clin Chim Acta. 2003 Feb;328(1-2):71-82. doi: 10.1016/s0009-8981(02)00373-x.
• [284] Functional Genomics and Its Bench-to-Bedside Translation Pertaining to the Identified Susceptibility Alleles and Loci in Ankylosing Spondylitis.Curr Rheumatol Rep. 2016 Oct;18(10):63. doi: 10.1007/s11926-016-0612-x.
• [285] Overexpression of cellular retinoic acid-binding protein type II (CRABP-II) and down-regulation of CRABP-I in psoriatic skin.Dermatology. 1992;185(4):251-6. doi: 10.1159/000247462.
• [286] Cornulin Is Induced in Psoriasis Lesions and Promotes Keratinocyte Proliferation via Phosphoinositide 3-Kinase/Akt Pathways.J Invest Dermatol. 2019 Jan;139(1):71-80. doi: 10.1016/j.jid.2018.06.184. Epub 2018 Sep 25.
• [287] Towards the development of a RNAi-based topical treatment for psoriasis: Proof-of-concept in a 3D psoriasis skin model.Exp Dermatol. 2018 May;27(5):463-469. doi: 10.1111/exd.13414. Epub 2017 Nov 2.
• [288] Overexpression of Drosha, DiGeorge syndrome critical region gene 8 (DGCR8), and Dicer mRNAs in the pathogenesis of psoriasis.J Cosmet Dermatol. 2017 Dec;16(4):e48-e53. doi: 10.1111/jocd.12336. Epub 2017 Mar 25.
• [289] The epigenetic mechanism for discordance of autoimmunity in monozygotic twins.J Autoimmun. 2017 Sep;83:43-50. doi: 10.1016/j.jaut.2017.04.003. Epub 2017 Apr 12.
• [290] Homeostatic Function of Dermokine in the Skin Barrier and Inflammation.J Invest Dermatol. 2020 Apr;140(4):838-849.e9. doi: 10.1016/j.jid.2019.09.011. Epub 2019 Oct 25.
• [291] Does imiquimod pretreatment optimize 308-nm excimer laser (UVB) therapy in psoriasis patients?.Photodermatol Photoimmunol Photomed. 2017 Jul;33(4):193-202. doi: 10.1111/phpp.12299. Epub 2017 Apr 20.
• [292] Tnfa signaling through tnfr2 protects skin against oxidative stress-induced inflammation.PLoS Biol. 2014 May 6;12(5):e1001855. doi: 10.1371/journal.pbio.1001855. eCollection 2014 May.
• [293] Overexpression of the oncofetal Fn variant containing the EDA splice-in segment in the dermal-epidermal junction of psoriatic uninvolved skin.J Invest Dermatol. 2000 Apr;114(4):706-11. doi: 10.1046/j.1523-1747.2000.00871.x.
• [294] Levels of miR-31 and its target genes in dermal mesenchymal cells of patients with psoriasis.Int J Dermatol. 2019 Feb;58(2):198-204. doi: 10.1111/ijd.14197. Epub 2018 Sep 9.
• [295] Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.Expert Rev Clin Immunol. 2019 Jun;15(6):589-597. doi: 10.1080/1744666X.2019.1601014. Epub 2019 Apr 12.
• [296] Five regulatory genes detected by matching signatures of eQTL and GWAS in psoriasis.J Dermatol Sci. 2014 Nov;76(2):139-42. doi: 10.1016/j.jdermsci.2014.07.007. Epub 2014 Aug 13.
• [297] Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.Arch Dermatol Res. 2018 Aug;310(6):475-483. doi: 10.1007/s00403-018-1825-9. Epub 2018 Mar 24.
• [298] Chronic Psoriatic Skin Inflammation Leads to Increased Monocyte Adhesion and Aggregation.J Immunol. 2015 Sep 1;195(5):2006-18. doi: 10.4049/jimmunol.1402307. Epub 2015 Jul 29.
• [299] Genotypic variability-based genome-wide association study identifies non-additive loci HLA-C and IL12B for psoriasis.J Hum Genet. 2018 Mar;63(3):289-296. doi: 10.1038/s10038-017-0350-6. Epub 2017 Dec 19.
• [300] Genetic Study on Small Insertions and Deletions in Psoriasis Reveals a Role in Complex Human Diseases.J Invest Dermatol. 2019 Nov;139(11):2302-2312.e14. doi: 10.1016/j.jid.2019.03.1157. Epub 2019 May 10.
• [301] Wnt/-Catenin and Wnt5a/Ca Pathways Regulate Proliferation and Apoptosis of Keratinocytes in Psoriasis Lesions.Cell Physiol Biochem. 2015;36(5):1890-902. doi: 10.1159/000430158. Epub 2015 Jul 17.
• [302] MiR-99a inhibits keratinocyte proliferation by targeting Frizzled-5 (FZD5) / FZD8 through -catenin signaling in psoriasis.Pharmazie. 2017 Aug 1;72(8):461-467. doi: 10.1691/ph.2017.7018.
• [303] Lack of Galanin Receptor 3 Alleviates Psoriasis by Altering Vascularization, Immune Cell Infiltration, and CytokineExpression.J Invest Dermatol. 2018 Jan;138(1):199-207. doi: 10.1016/j.jid.2017.08.015. Epub 2017 Aug 24.
• [304] Regulatory role for Krppel-like zinc-finger protein Gli-similar 1 (Glis1) in PMA-treated and psoriatic epidermis.J Invest Dermatol. 2006 Jan;126(1):49-60. doi: 10.1038/sj.jid.5700018.
• [305] Systemic and Local Increase of Granulysin Expression in Cytotoxic Lymphocytes in Severe Psoriasis.Acta Derm Venereol. 2019 Nov 1;99(12):1136-1142. doi: 10.2340/00015555-3298.
• [306] GPR15 is not critically involved in the regulation of murine psoriasiform dermatitis.J Dermatol Sci. 2019 Apr;94(1):196-204. doi: 10.1016/j.jdermsci.2019.01.008. Epub 2019 Mar 12.
• [307] Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin.J Invest Dermatol. 1996 Feb;106(2):269-74. doi: 10.1111/1523-1747.ep12340668.
• [308] The Grainyhead transcription factor Grhl3/Get1 suppresses miR-21 expression and tumorigenesis in skin: modulation of the miR-21 target MSH2 by RNA-binding protein DND1.Oncogene. 2013 Mar 21;32(12):1497-507. doi: 10.1038/onc.2012.168. Epub 2012 May 21.
• [309] Association between genetic polymorphisms of glutathione S-transferase M1/T1 and psoriasis in a population from the area of the strict of messina (Southern Italy).Free Radic Res. 2020 Jan;54(1):57-63. doi: 10.1080/10715762.2019.1698738. Epub 2019 Dec 10.
• [310] Granzyme A potentiates chemokine production in IL-17-stimulated keratinocytes.Exp Dermatol. 2017 Sep;26(9):824-827. doi: 10.1111/exd.13284. Epub 2017 Apr 10.
• [311] Efficacy and safety of HAT1 compared with calcipotriol in the treatment of patients with mild to moderate chronic plaque psoriasis: results from an open-label randomized comparative pilot clinical study.Clin Exp Dermatol. 2020 Apr;45(3):318-322. doi: 10.1111/ced.14074. Epub 2019 Sep 26.
• [312] Genome-wide DNA methylation analysis in ankylosing spondylitis identifies HLA-B*27 dependent and independent DNA methylation changes in whole blood.J Autoimmun. 2019 Aug;102:126-132. doi: 10.1016/j.jaut.2019.04.022. Epub 2019 May 23.
• [313] Association of TAP and HLA-DM genes with psoriasis in Koreans.J Invest Dermatol. 2003 Apr;120(4):616-22. doi: 10.1046/j.1523-1747.2003.12091.x.
• [314] Lack of association between cytotoxic T-lymphocyte antigen-4+49A/G polymorphism and psoriasis and vitiligo: A meta-analysis of case-control studies.Gene. 2015 Sep 1;568(2):196-202. doi: 10.1016/j.gene.2015.05.051. Epub 2015 May 24.
• [315] Psoriasis regression analysis of MHC loci identifies shared genetic variants with vitiligo.PLoS One. 2011;6(11):e23089. doi: 10.1371/journal.pone.0023089. Epub 2011 Nov 18.
• [316] Deletion of the activating NKG2C receptor and a functional polymorphism in its ligand HLA-E in psoriasis susceptibility.Exp Dermatol. 2013 Oct;22(10):679-81. doi: 10.1111/exd.12233.
• [317] Effect of alterations in apoptotic pathway on development of metabolic syndrome in patients with psoriasis vulgaris.Br J Dermatol. 2017 Jun;176(6):1549-1557. doi: 10.1111/bjd.15185. Epub 2017 Apr 10.
• [318] Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors.Inflamm Res. 2019 Jul;68(7):557-567. doi: 10.1007/s00011-019-01238-8. Epub 2019 May 6.
• [319] Parakeratosis in skin is associated with loss of inhibitor of differentiation 4 via promoter methylation.Hum Pathol. 2011 Dec;42(12):1878-87. doi: 10.1016/j.humpath.2011.02.005. Epub 2011 Jun 12.
• [320] Serum IFI16 and anti-IFI16 antibodies in psoriatic arthritis.Clin Exp Immunol. 2020 Jan;199(1):88-96. doi: 10.1111/cei.13376. Epub 2019 Oct 15.
• [321] Pso p27, a SERPINB3/B4-derived protein, is most likely a common autoantigen in chronic inflammatory diseases.Clin Immunol. 2017 Jan;174:10-17. doi: 10.1016/j.clim.2016.11.006. Epub 2016 Nov 15.
• [322] The anti-apoptotic protein G1P3 is overexpressed in psoriasis and regulated by the non-coding RNA, PRINS.Exp Dermatol. 2010 Mar;19(3):269-78. doi: 10.1111/j.1600-0625.2010.01066.x.
• [323] IL28RA inhibits human epidermal keratinocyte proliferation by inhibiting cell cycle progression.Mol Biol Rep. 2019 Feb;46(1):1189-1197. doi: 10.1007/s11033-019-04586-0. Epub 2019 Jan 10.
• [324] Gene-gene interactions in IL23/Th17 pathway contribute to psoriasis susceptibility in Chinese Han population.J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1156-62. doi: 10.1111/j.1468-3083.2012.04683.x. Epub 2012 Aug 22.
• [325] IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema.J Eur Acad Dermatol Venereol. 2020 Apr;34(4):800-809. doi: 10.1111/jdv.16126. Epub 2020 Jan 19.
• [326] Ultraviolet B Inhibits IL-17A/TNF--Stimulated Activation of Human Dermal Fibroblasts by Decreasing the Expression of IL-17RA and IL-17RC on Fibroblasts.Front Immunol. 2017 Feb 3;8:91. doi: 10.3389/fimmu.2017.00091. eCollection 2017.
• [327] Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation.Sci Immunol. 2019 Jun 7;4(36):eaau9657. doi: 10.1126/sciimmunol.aau9657.
• [328] IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential.Int J Mol Sci. 2019 Mar 13;20(6):1257. doi: 10.3390/ijms20061257.
• [329] Association analysis of IL20RA and IL20RB genes in psoriasis.Genes Immun. 2008 Jul;9(5):445-51. doi: 10.1038/gene.2008.36. Epub 2008 May 15.
• [330] Ultrasound targeting of Q-starch/miR-197 complexes for topical treatment of psoriasis.J Control Release. 2018 Aug 28;284:103-111. doi: 10.1016/j.jconrel.2018.05.040. Epub 2018 Jun 2.
• [331] Regulation of IL-22BP in psoriasis.Sci Rep. 2018 Mar 23;8(1):5085. doi: 10.1038/s41598-018-23510-3.
• [332] Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis.MAbs. 2019 Nov-Dec;11(8):1428-1442. doi: 10.1080/19420862.2019.1654305. Epub 2019 Aug 18.
• [333] Immune Control by TRAF6-Mediated Pathways of Epithelial Cells in the EIME (Epithelial Immune Microenvironment).Front Immunol. 2019 May 16;10:1107. doi: 10.3389/fimmu.2019.01107. eCollection 2019.
• [334] Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis.PLoS One. 2013;8(1):e51752. doi: 10.1371/journal.pone.0051752. Epub 2013 Jan 15.
• [335] Variation at the IRF2 gene and susceptibility to psoriasis in chromosome 4q-linked families.J Invest Dermatol. 2004 Mar;122(3):640-3. doi: 10.1046/j.0022-202X.2004.22135.x.
• [336] Reduced CD18 levels drive regulatory T cell conversion into Th17 cells in the CD18hypo PL/J mouse model of psoriasis.J Immunol. 2013 Mar 15;190(6):2544-53. doi: 10.4049/jimmunol.1202399. Epub 2013 Feb 15.
• [337] The (CCTTT) n pentanucleotide repeat polymorphism in the inducible nitric oxide synthase gene promoter and the risk of psoriasis in Taiwanese.Arch Dermatol Res. 2015 Jul;307(5):425-32. doi: 10.1007/s00403-015-1542-6. Epub 2015 Feb 8.
• [338] Accumulation of FLT3(+) CD11c (+) dendritic cells in psoriatic lesions and the anti-psoriatic effect of a selective FLT3 inhibitor.Immunol Res. 2014 Oct;60(1):112-26. doi: 10.1007/s12026-014-8521-4.
• [339] Omentin serum levels and omentin gene Val109Asp polymorphism in patients with psoriasis.Int J Dermatol. 2014 May;53(5):601-5. doi: 10.1111/ijd.12306. Epub 2013 Dec 10.
• [340] Downregulation of involucrin in psoriatic lesions following therapy with propylthiouracil, an anti-thyroid thioureylene: immunohistochemistry and gene expression analysis.Int J Dermatol. 2015 Mar;54(3):302-6. doi: 10.1111/ijd.12565. Epub 2014 Sep 30.
• [341] Human leukocyte antigen (HLA)-C polymorphisms are associated with a decreased risk of rheumatoid arthritis.Mol Biol Rep. 2014 Jun;41(6):4103-8. doi: 10.1007/s11033-014-3280-9. Epub 2014 Feb 25.
• [342] Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes.Exp Dermatol. 2017 Nov;26(11):1112-1117. doi: 10.1111/exd.13393. Epub 2017 Aug 25.
• [343] Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris.J Invest Dermatol. 2004 May;122(5):1133-6. doi: 10.1111/j.0022-202X.2004.22517.x.
• [344] Psoriasis patients are enriched for genetic variants that protect against HIV-1 disease.PLoS Genet. 2012 Feb;8(2):e1002514. doi: 10.1371/journal.pgen.1002514. Epub 2012 Feb 16.
• [345] MiR-744-3p regulates keratinocyte proliferation and differentiation via targeting KLLN in psoriasis.Exp Dermatol. 2019 Mar;28(3):283-291. doi: 10.1111/exd.13888.
• [346] IL-17 and IL-22 Promote Keratinocyte Stemness in the Germinative Compartment in Psoriasis.J Invest Dermatol. 2019 Jul;139(7):1564-1573.e8. doi: 10.1016/j.jid.2019.01.014. Epub 2019 Jan 23.
• [347] IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production.J Immunol. 2014 Feb 15;192(4):1815-23. doi: 10.4049/jimmunol.1300047. Epub 2014 Jan 22.
• [348] Pushing the Envelope in Psoriasis: Late Cornified Envelope Proteins Possess Antimicrobial Activity.J Invest Dermatol. 2017 Nov;137(11):2257-2259. doi: 10.1016/j.jid.2017.08.026.
• [349] A large-scale screen for coding variants predisposing to psoriasis.Nat Genet. 2014 Jan;46(1):45-50. doi: 10.1038/ng.2827. Epub 2013 Nov 10.
• [350] LMO4 Is a Disease-Provocative Transcription Coregulator Activated by IL-23 in Psoriatic Keratinocytes.J Invest Dermatol. 2018 May;138(5):1078-1087. doi: 10.1016/j.jid.2017.12.010. Epub 2017 Dec 16.
• [351] Fumaric acid esters for psoriasis: a systematic review.Ir J Med Sci. 2017 Feb;186(1):161-177. doi: 10.1007/s11845-016-1470-2. Epub 2016 Jun 7.
• [352] SLURP-2, a novel member of the human Ly-6 superfamily that is up-regulated in psoriasis vulgaris.Genomics. 2003 Jan;81(1):26-33. doi: 10.1016/s0888-7543(02)00025-3.
• [353] Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis.J Invest Dermatol. 2016 Mar;136(3):593-602. doi: 10.1016/j.jid.2015.11.026. Epub 2015 Dec 29.
• [354] Matrix metalloproteinase-19 expression in normal and diseased skin: dysregulation by epidermal proliferation.J Invest Dermatol. 2003 Nov;121(5):989-96. doi: 10.1046/j.1523-1747.2003.12526.x.
• [355] Burden of chronic urticaria relative to psoriasis in five European countries.J Eur Acad Dermatol Venereol. 2018 Feb;32(2):282-290. doi: 10.1111/jdv.14584. Epub 2017 Oct 12.
• [356] Altered expression of matrix remodelling associated 7 (MXRA7) in psoriatic epidermis: Evidence for a protective role in the psoriasis imiquimod mouse model.Exp Dermatol. 2018 Sep;27(9):1038-1042. doi: 10.1111/exd.13687.
• [357] Non-M protein(s) on the cell wall and membrane of group A streptococci induce(s) IFN-gamma production by dermal CD4+ T cells in psoriasis.Arch Dermatol Res. 2001 Apr;293(4):165-70. doi: 10.1007/s004030100218.
• [358] Comparison of Hospital Anxiety and Depression Scale (HADS) and Zung Self-Rating Anxiety/Depression Scale (SAS/SDS) in Evaluating Anxiety and Depression in Patients with Psoriatic Arthritis.Dermatology. 2020;236(2):170-178. doi: 10.1159/000498848. Epub 2019 Aug 21.
• [359] Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17 686 women: the Women's Genome Health Study.Circ Cardiovasc Genet. 2009 Apr;2(2):134-41. doi: 10.1161/CIRCGENETICS.108.825273. Epub 2009 Feb 12.
• [360] A CD40 and an NCOA5 gene polymorphism confer susceptibility to psoriasis in a Southern European population: a case-control study.Hum Immunol. 2011 Sep;72(9):761-5. doi: 10.1016/j.humimm.2011.05.014. Epub 2011 May 24.
• [361] A preliminary examination of the role of NFAT 3 in human skin, cultured keratocytes and dermal fibroblasts.J Cutan Pathol. 2010 Sep;37(9):e21-36. doi: 10.1111/j.1600-0560.2009.01313.x.
• [362] Association with Genetic Variants in the IL-23 and NF-B Pathways Discriminates between Mild and Severe Psoriasis Skin Disease.J Invest Dermatol. 2015 Aug;135(8):1969-1976. doi: 10.1038/jid.2015.103. Epub 2015 Mar 19.
• [363] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [364] Novel roles of NM23 proteins in skin homeostasis, repair and disease.Oncogene. 2007 Jan 25;26(4):532-42. doi: 10.1038/sj.onc.1209822. Epub 2006 Jul 24.
• [365] Overexpression and potential roles of NRIP1 in psoriasis.Oncotarget. 2016 Nov 8;7(45):74236-74246. doi: 10.18632/oncotarget.12371.
• [366] Role of neurturin in spontaneous itch and increased nonpeptidergic intraepidermal fiber density in a mouse model of psoriasis.Pain. 2017 Nov;158(11):2196-2202. doi: 10.1097/j.pain.0000000000001025.
• [367] Epigenetic regulation of OAS2 shows disease-specific DNA methylation profiles at individual CpG sites.Sci Rep. 2016 Aug 30;6:32579. doi: 10.1038/srep32579.
• [368] Unraveling the genetics of complex diseases: susceptibility genes for rheumatoid arthritis and psoriasis.Semin Immunol. 2009 Dec;21(6):318-27. doi: 10.1016/j.smim.2009.04.002. Epub 2009 May 14.
• [369] Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.J Dermatolog Treat. 2017 Feb;28(1):3-7. doi: 10.1080/09546634.2016.1214671. Epub 2016 Aug 18.
• [370] Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis.Genes Immun. 2004 Mar;5(2):117-21. doi: 10.1038/sj.gene.6364046.
• [371] Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model.J Steroid Biochem Mol Biol. 2019 Apr;188:8-16. doi: 10.1016/j.jsbmb.2018.11.017. Epub 2018 Nov 30.
• [372] Affinity of 22-oxa-1,25(OH)2D3 for 1,25-dihydroxyvitamin D receptor and its effects on the synthesis of osteocalcin in human osteosarcoma cells.Biochem Biophys Res Commun. 1990 Jun 15;169(2):629-35. doi: 10.1016/0006-291x(90)90377-y.
• [373] Overexpressed fibulin-3 contributes to the pathogenesis of psoriasis by promoting angiogenesis.Clin Exp Dermatol. 2019 Jun;44(4):e64-e72. doi: 10.1111/ced.13720. Epub 2018 Aug 26.
• [374] Inositoylated platelet-activating factor (Ino-C2-PAF) modulates dynamic lymphocyte-endothelial cell interactions and alleviates psoriasis-like skin inflammation in two complementary mouse models.J Invest Dermatol. 2014 Oct;134(10):2510-2520. doi: 10.1038/jid.2014.170. Epub 2014 Apr 8.
• [375] Podoplanin in Inflammation and Cancer.Int J Mol Sci. 2019 Feb 6;20(3):707. doi: 10.3390/ijms20030707.
• [376] The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment.Oncotarget. 2017 Oct 6;8(58):98580-98597. doi: 10.18632/oncotarget.21651. eCollection 2017 Nov 17.
• [377] Association of psoriasis to PGLYRP and SPRR genes at PSORS4 locus on 1q shows heterogeneity between Finnish, Swedish and Irish families.Exp Dermatol. 2009 Feb;18(2):109-15. doi: 10.1111/j.1600-0625.2008.00769.x. Epub 2008 Jul 17.
• [378] Peptidoglycan recognition proteins Pglyrp3 and Pglyrp4 are encoded from the epidermal differentiation complex and are candidate genes for the Psors4 locus on chromosome 1q21.Hum Genet. 2006 Mar;119(1-2):113-25. doi: 10.1007/s00439-005-0115-8. Epub 2005 Dec 17.
• [379] Serum elafin as a potential inflammatory marker in psoriasis.Int J Dermatol. 2019 Feb;58(2):205-209. doi: 10.1111/ijd.14217. Epub 2018 Sep 9.
• [380] Regulation of the psoriatic chemokine CCL20 by E3 ligases Trim32 and Piasy in keratinocytes.J Invest Dermatol. 2010 May;130(5):1384-90. doi: 10.1038/jid.2009.416. Epub 2010 Jan 7.
• [381] Crossed looks on the dermatologist's position and the patient's preoccupations as to psoriasis and pregnancy: preliminary results of the PREGNAN-PSO study.J Eur Acad Dermatol Venereol. 2019 May;33(5):880-885. doi: 10.1111/jdv.15423. Epub 2019 Feb 27.
• [382] Characterization and differentiation-dependent regulation of secreted phospholipases A in human keratinocytes and in healthy and psoriatic human skin.J Invest Dermatol. 2005 Jan;124(1):204-11. doi: 10.1111/j.0022-202X.2004.23513.x.
• [383] Epidermal phospholipase C1 regulates granulocyte counts and systemic interleukin-17 levels in mice.Nat Commun. 2012 Jul 17;3:963. doi: 10.1038/ncomms1960.
• [384] Splicing factors differentially expressed in psoriasis alter mRNA maturation of disease-associated EDA+fibronectin.Mol Cell Biochem. 2017 Dec;436(1-2):189-199. doi: 10.1007/s11010-017-3090-1. Epub 2017 Jun 6.
• [385] The proteasome maturation protein POMP increases proteasome assembly and activity in psoriatic lesional skin.J Dermatol Sci. 2017 Oct;88(1):10-19. doi: 10.1016/j.jdermsci.2017.04.009. Epub 2017 Apr 30.
• [386] Elevated platelet activation in patients with atopic dermatitis and psoriasis: increased plasma levels of beta-thromboglobulin and platelet factor 4.Allergol Int. 2008 Dec;57(4):391-6. doi: 10.2332/allergolint.O-08-537. Epub 2008 Dec 1.
• [387] MiR-548a-3p Promotes Keratinocyte Proliferation Targeting PPP3R1 after Being Induced by IL-22.Inflammation. 2018 Mar;41(2):496-504. doi: 10.1007/s10753-017-0705-3.
• [388] NF-B-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis.Nat Commun. 2015 Jul 3;6:7652. doi: 10.1038/ncomms8652.
• [389] Prokineticin 2 Plays a Pivotal Role in Psoriasis.EBioMedicine. 2016 Nov;13:248-261. doi: 10.1016/j.ebiom.2016.10.022. Epub 2016 Oct 19.
• [390] Association of skin barrier genes within the PSORS4 locus is enriched in Singaporean Chinese with early-onset psoriasis.J Invest Dermatol. 2009 Mar;129(3):606-14. doi: 10.1038/jid.2008.273. Epub 2008 Sep 11.
• [391] Role of ceramides in barrier function of healthy and diseased skin.Am J Clin Dermatol. 2005;6(4):215-23. doi: 10.2165/00128071-200506040-00002.
• [392] HLA-C*06:02-independent, gender-related association of PSORS1C3 and PSORS1C1/CDSN single-nucleotide polymorphisms with risk and severity of psoriasis.Mol Genet Genomics. 2018 Aug;293(4):957-966. doi: 10.1007/s00438-018-1435-4. Epub 2018 Mar 27.
• [393] Correlation of HLA-Cw*06 allele frequency with some clinical features of psoriasis vulgaris in the population of northern Poland.J Appl Genet. 2004;45(4):473-6.
• [394] Pituitary tumor transforming gene PTTG2 induces psoriasis by regulating vimentin and E-cadherin expression.Int J Clin Exp Pathol. 2015 Sep 1;8(9):10887-93. eCollection 2015.
• [395] Evidence on the direct correlation between miR-31 and IL-22 axis in IMQ-induced psoriasis.Exp Dermatol. 2019 Nov;28(11):1336-1340. doi: 10.1111/exd.14001. Epub 2019 Oct 22.
• [396] A Framework for Multi-Omic Prediction ofTreatment Response to Biologic Therapyfor Psoriasis.J Invest Dermatol. 2019 Jan;139(1):100-107. doi: 10.1016/j.jid.2018.04.041. Epub 2018 Jul 17.
• [397] Loss of the Epigenetic Mark 5-hmC in Psoriasis: Implications for Epidermal Stem Cell Dysregulation.J Invest Dermatol. 2020 Jun;140(6):1266-1275.e3. doi: 10.1016/j.jid.2019.10.016. Epub 2019 Dec 11.
• [398] Analysis of serum chemerin concentrations in psoriatic patients in relation to metabolic abnormalities.Postepy Dermatol Alergol. 2019 Oct;36(5):531-537. doi: 10.5114/ada.2019.89503. Epub 2019 Nov 12.
• [399] Expression and potential role of cellular retinol binding protein I in psoriasis.Oncotarget. 2018 Dec 4;9(95):36736-36749. doi: 10.18632/oncotarget.26314. eCollection 2018 Dec 4.
• [400] Biomarkers of Inflammation in Obesity-Psoriatic Patients.Mediators Inflamm. 2019 May 28;2019:7353420. doi: 10.1155/2019/7353420. eCollection 2019.
• [401] RNase 7 downregulates TH2 cytokine production by activated human T cells.Allergy. 2017 Nov;72(11):1694-1703. doi: 10.1111/all.13173. Epub 2017 Jun 21.
• [402] The application of strand invasion phenomenon, directed by peptide nucleic acid (PNA) and single-stranded DNA binding protein (SSB) for the recognition of specific sequences of human endogenous retroviral HERV-W family.J Mol Recognit. 2017 May;30(5). doi: 10.1002/jmr.2600. Epub 2016 Dec 6.
• [403] Maresin-1 suppresses imiquimod-induced skin inflammation by regulating IL-23 receptor expression.Sci Rep. 2018 Apr 3;8(1):5522. doi: 10.1038/s41598-018-23623-9.
• [404] Can signal peptide-CUB-EGF domain-containing protein (SCUBE) levels be a marker of angiogenesis in patients with psoriasis?.Arch Dermatol Res. 2017 Apr;309(3):203-207. doi: 10.1007/s00403-017-1722-7. Epub 2017 Feb 25.
• [405] Association analyses identify six new psoriasis susceptibility loci in the Chinese population.Nat Genet. 2010 Nov;42(11):1005-9. doi: 10.1038/ng.690. Epub 2010 Oct 17.
• [406] Tristetraprolin expression by keratinocytes controls local and systemic inflammation.JCI Insight. 2017 Jun 2;2(11):e92979. doi: 10.1172/jci.insight.92979. eCollection 2017 Jun 2.
• [407] Innate immune adaptor MyD88 deficiency prevents skin inflammation in SHARPIN-deficient mice.Cell Death Differ. 2019 Mar;26(4):741-750. doi: 10.1038/s41418-018-0159-7. Epub 2018 Jul 23.
• [408] Lesional upregulation of SLURP1 immunostaining parallels disease severity in psoriasis vulgaris patients.J Dtsch Dermatol Ges. 2018 Nov;16(11):1329-1337. doi: 10.1111/ddg.13682.
• [409] notch2, notch4 gene polymorphisms in psoriasis vulgaris.Eur J Dermatol. 2013 Apr 1;23(2):146-53. doi: 10.1684/ejd.2013.1985.
• [410] Effects of Human Mesenchymal Stem Cells Transduced with Superoxide Dismutase on Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice.Antioxid Redox Signal. 2016 Feb 10;24(5):233-48. doi: 10.1089/ars.2015.6368. Epub 2015 Nov 18.
• [411] TNF- and IL-17A induce the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.J Dermatol Sci. 2019 Oct;96(1):26-32. doi: 10.1016/j.jdermsci.2019.08.007. Epub 2019 Aug 21.
• [412] The serine protease inhibitor of Kazal-type 7 (SPINK7) is expressed in human skin.Arch Dermatol Res. 2017 Nov;309(9):767-771. doi: 10.1007/s00403-017-1773-9. Epub 2017 Aug 29.
• [413] Multi-omics study in monozygotic twins confirm the contribution of de novo mutation to psoriasis.J Autoimmun. 2020 Jan;106:102349. doi: 10.1016/j.jaut.2019.102349. Epub 2019 Oct 16.
• [414] Loss of serum response factor in keratinocytes results in hyperproliferative skin disease in mice.J Clin Invest. 2009 Apr;119(4):899-910. doi: 10.1172/JCI37771. Epub 2009 Mar 23.
• [415] 'Psoriasis 1' reduces psoriasislike skin inflammation by inhibiting the VDRmediated nuclear NFB and STAT signaling pathways.Mol Med Rep. 2018 Sep;18(3):2733-2743. doi: 10.3892/mmr.2018.9262. Epub 2018 Jul 9.
• [416] microRNA-130a Promotes Human Keratinocyte Viability and Migration and Inhibits Apoptosis Through Direct Regulation of STK40-Mediated NF-B Pathway and Indirect Regulation of SOX9-Meditated JNK/MAPK Pathway: A Potential Role in Psoriasis.DNA Cell Biol. 2017 Mar;36(3):219-226. doi: 10.1089/dna.2016.3517. Epub 2017 Jan 13.
• [417] T-cell activation RhoGTPase-activating protein plays an important role in T(H)17-cell differentiation.Immunol Cell Biol. 2017 Sep;95(8):729-735. doi: 10.1038/icb.2017.27. Epub 2017 May 2.
• [418] The mRNA expression and promoter methylation status of the p16 gene in colony-forming cells with high proliferative potential in patients with psoriasis.Clin Exp Dermatol. 2007 Nov;32(6):702-8. doi: 10.1111/j.1365-2230.2007.02458.x. Epub 2007 May 17.
• [419] Expression of tolerance associated gene-1, a mitochondrial protein inhibiting T cell activation, can be used to predict response to immune modulating therapies.J Immunol. 2009 Sep 15;183(6):4077-87. doi: 10.4049/jimmunol.0804351. Epub 2009 Aug 14.
• [420] Inflammatory peeling skin syndrome caused by homozygous genomic deletion in the PSORS1 region encompassing the CDSN gene.Exp Dermatol. 2014 Jan;23(1):60-3. doi: 10.1111/exd.12292.
• [421] Novel methotrexate soft nanocarrier/fractional erbium YAG laser combination for clinical treatment of plaque psoriasis.Artif Cells Nanomed Biotechnol. 2018;46(sup1):996-1002. doi: 10.1080/21691401.2018.1440236. Epub 2018 Feb 15.
• [422] Interferon- decreases ceramides with long-chain fatty acids: possible involvement in atopic dermatitis and psoriasis.J Invest Dermatol. 2014 Mar;134(3):712-718. doi: 10.1038/jid.2013.364. Epub 2013 Sep 5.
• [423] Ginsenoside Rg1 abolish imiquimod-induced psoriasis-like dermatitis in BALB/c mice via downregulating NF-B signaling pathway.J Food Biochem. 2019 Nov;43(11):e13032. doi: 10.1111/jfbc.13032. Epub 2019 Sep 9.
• [424] Loss of TIPE2 Has Opposing Effects on the Pathogenesis of Autoimmune Diseases.Front Immunol. 2019 Sep 24;10:2284. doi: 10.3389/fimmu.2019.02284. eCollection 2019.
• [425] CD30L/CD30 protects against psoriasiform skin inflammation by suppressing Th17-related cytokine production by V4(+) T cells.J Autoimmun. 2019 Jul;101:70-85. doi: 10.1016/j.jaut.2019.04.009. Epub 2019 Apr 18.
• [426] Rapamycin ameliorates psoriasis by regulating the expression and methylation levels of tropomyosin via ERK1/2 and mTOR pathways in vitro and in vivo.Exp Dermatol. 2018 Oct;27(10):1112-1119. doi: 10.1111/exd.13745. Epub 2018 Aug 3.
• [427] The Act1 D10N missense variant impairs CD40 signaling in human B-cells.Genes Immun. 2019 Jan;20(1):23-31. doi: 10.1038/s41435-017-0007-7. Epub 2018 Jan 5.
• [428] TREX through Cutaneous HealthandDisease.J Invest Dermatol. 2016 Dec;136(12):2337-2339. doi: 10.1016/j.jid.2016.06.628.
• [429] Structural insights into the duplex DNA processing of TREX2.Nucleic Acids Res. 2018 Dec 14;46(22):12166-12176. doi: 10.1093/nar/gky970.
• [430] E3 Ligase Trim21 Ubiquitylates and Stabilizes Keratin 17 to Induce STAT3 Activation in Psoriasis.J Invest Dermatol. 2018 Dec;138(12):2568-2577. doi: 10.1016/j.jid.2018.05.016. Epub 2018 May 31.
• [431] Trim32 Deficiency Enhances Th2 Immunity and Predisposes to Features of Atopic Dermatitis.J Invest Dermatol. 2017 Feb;137(2):359-366. doi: 10.1016/j.jid.2016.09.020. Epub 2016 Oct 5.
• [432] Glucocorticoids and Glucocorticoid-Induced-Leucine-Zipper (GILZ) in Psoriasis.Front Immunol. 2019 Sep 13;10:2220. doi: 10.3389/fimmu.2019.02220. eCollection 2019.
• [433] The Tetratricopeptide repeat domain 7 gene is mutated in flaky skin mice: a model for psoriasis, autoimmunity, and anemia.Exp Biol Med (Maywood). 2005 Oct;230(9):659-67. doi: 10.1177/153537020523000908.
• [434] Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders.Front Immunol. 2019 Jul 26;10:1764. doi: 10.3389/fimmu.2019.01764. eCollection 2019.
• [435] Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studies.Cutis. 2019 Feb;103(2):111-116.
• [436] CXCL17 Attenuates Imiquimod-Induced Psoriasis-like Skin Inflammation by Recruiting Myeloid-Derived Suppressor Cells and Regulatory T Cells.J Immunol. 2017 May 15;198(10):3897-3908. doi: 10.4049/jimmunol.1601607. Epub 2017 Apr 7.
• [437] Silencing KRT16 inhibits keratinocyte proliferation and VEGF secretion in psoriasis via inhibition of ERK signaling pathway.Kaohsiung J Med Sci. 2019 May;35(5):284-296. doi: 10.1002/kjm2.12034. Epub 2019 Apr 3.
• [438] In vivo anti-psoriatic activity, biodistribution, sub-acute and sub-chronic toxicity studies of orally administered methotrexate loaded chitin nanogel in comparison with methotrexate tablet.Int J Biol Macromol. 2018 Apr 15;110:259-268. doi: 10.1016/j.ijbiomac.2018.01.036. Epub 2018 Feb 2.
• [439] IB is a key player in the antipsoriatic effects of secukinumab.J Allergy Clin Immunol. 2020 Jan;145(1):379-390. doi: 10.1016/j.jaci.2019.09.029. Epub 2019 Oct 14.
• [440] RIG-I antiviral signaling drives interleukin-23 production and psoriasis-like skin disease.EMBO Mol Med. 2017 May;9(5):589-604. doi: 10.15252/emmm.201607027.
• [441] Gene from a psoriasis susceptibility locus primes the skin for inflammation.Sci Transl Med. 2010 Dec 8;2(61):61ra90. doi: 10.1126/scitranslmed.3001108.
• [442] Serum levels of psoriasin (S100A7) and koebnerisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis.Clin Exp Dermatol. 2018 Apr;43(3):262-267. doi: 10.1111/ced.13370. Epub 2018 Jan 14.
• [443] Janus kinase/signal transducer and activator of transcription pathways in spondyloarthritis.Curr Opin Rheumatol. 2017 Jul;29(4):311-316. doi: 10.1097/BOR.0000000000000399.
• [444] ROC analysis of selected matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in psoriatic patients.Postepy Dermatol Alergol. 2018 Apr;35(2):167-173. doi: 10.5114/ada.2018.75238. Epub 2018 Apr 24.
• [445] A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N Engl J Med. 2001 Oct 18;345(16):1167-75. doi: 10.1056/NEJMoa002939.